| Entries |
| Document | Title | Date |
|---|
| 20080199531 | Methods And Products For Delivering Biological Molecules To Cells Using Multicomponent Nanostructures - This invention is predicated on the present applicants' discovery that nanostructures comprising discrete regions of different composition can be used to deliver to a biological cell a desired combination of molecules in close proximity. Different molecules can be selectively bonded to discrete regions of different composition in sufficiently close physical relationship to enhance delivery or effectiveness within the cell. The preferred nanostructures are multicomponent nanorods. Important applications include delivery of missing DNA sequences for gene therapy and delivery of antigens or DNA encoding antigens for vaccination. | 08-21-2008 |
| 20080206348 | Cilostazol-Containing Pharmaceutical Composition Based On Particles Of Less Than 50 Micrometers - The present invention relates to cilostazol compositions, process for their preparation, and methods for their administration to treat a condition. In the cilostazol compositions, | 08-28-2008 |
| 20080213383 | FINE PARTICLES OF POORLY WATER-SOLUBLE DRUG HAVING ENTERIC MATERIAL ADSORBED ON PARTICLE SURFACE - The present invention relates to fine particles of a poorly water-soluble drug wherein a predetermined enteric material is adsorbed as the dispersant on the surface of a poorly water-soluble drug, as well as a method for producing the same fine particles. It is possible to efficiently and safely produce in a short amount of time fine particles with which absorption of a poorly water-soluble drug that is poorly absorbed in humans, and the like can be improved, and a pharmaceutical preparation with excellent dispersion stability can be provided, by using the fine particles of the present invention having an improved dissolution profile. | 09-04-2008 |
| 20080213384 | Ultrasound-Assisted Synthesis of Cyclodextrin-Based Nanosponges - A description is given of substantially spherical nanosponges which can be obtained by crosslinking cyclodextrins and their by-products with organic carbonates as crosslinkers and ultrasounds without a solvent. | 09-04-2008 |
| 20080213385 | Formulations for 7- (T-Butoxy) Iminomethyl Camptothecin - The present invention relates to nanoparticulate compositions in which the active agent is a topoisomerase I inhibitor and pharmaceutical compositions comprising the nanoparticulate compositions that are useful for the treatment and prevention of proliferative diseases including cancer. | 09-04-2008 |
| 20080226740 | Marine algal extracts comprising marine algal polysaccharides of low degree polymerizaton, and the preparation processes and uses thereof - Disclosed herein are marine algal extracts containing marine algal polysaccharides of low degree polymerization, and nanoparticles fabricated from the extracts. Preparation processes and applications of the marine algal extracts and the nanoparticles are also disclosed. | 09-18-2008 |
| 20080233199 | Coacervation Process - Methods of forming compositions for the sustained release of water soluble active agents, including biologically active polypeptides and products produced by the process are described. Improved product characteristics and ease of scale-up can be achieved using a novel coacervation process wherein at least one coacervation agent is added to the mixture comprising the active agent and the polymer in at least two distinct stages. | 09-25-2008 |
| 20080233200 | Nanoparticles for protein drug delivery - The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one bioactive agent characterized with a positive surface charge and their enhanced permeability for paracellular drug delivery. | 09-25-2008 |
| 20080241267 | Hydrogel Microspheres with Improved Release Profile - The invention provides an emulsion-based method for the preparation of controlled release microspheres for the delivery of active compounds. The method comprises the preparation of an emulsion comprising an aqueous dispersed phase which comprises a polymer capable of forming a hydrogel, a bioactive protein, and water, and which is substantially free from insoluble aggregates of the bioactive protein. Subsequently, the polymer physically or chemically crosslinked to form a hydrogel. The invention further provides active protein-loaded hydrogel microspheres which are prepared by the process, and which are substantially free from insoluble aggregates of the active protein. The microspheres exhibit controlled release, with release profiles which are considerably improved over those of previously known hydrogel microspheres. The microspheres may be used to deliver therapeutic or diagnostic proteins by injection. | 10-02-2008 |
| 20080241268 | COMPOSITIONS AND METHODS FOR WT1 SPECIFIC IMMUNOTHERAPY - Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases. | 10-02-2008 |
| 20080254132 | High pressure spray-dry of bioactive materials - This invention provides compositions and methods providing, e.g., stable powder particles containing bioactive materials. The methods include, e.g., high pressure spraying of the bioactive materials in solution or suspension, with viscosity enhancing agents and/or surfactants. Compositions of the invention provide, e.g., high initial purity, high stability in storage, and reconstitution at high concentrations. | 10-16-2008 |
| 20080260847 | Polymer-Based Sustained Release Device - This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar. | 10-23-2008 |
| 20080260848 | Compositions that Enable Rapid-Acting and Highly Absorptive Intranasal Administration - Powdery compositions for intranasal administration, which comprise non-peptide/non-protein drugs and as a carrier, crystalline cellulose aggregates having a particular cribriform particle diameter, yield rapid action and high absorbability of the drugs. | 10-23-2008 |
| 20080260849 | COMPOSITION FOR TRANSMUCOSAL ABSORPTION - It is an object of the present invention to provide a composition for transmucosal absorption which comprises highly safe protein nanoparticles having high transparency due to the small particle size and high transmucosal absorbability. The present invention provides a composition for transmucosal absorption which comprises protein nanoparticles containing an active ingredient and having an average particle size of 10 nm to 300 nm. | 10-23-2008 |
| 20080279954 | Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network - A method of preparing a supramolecular complex containing at least one therapeutic agent and a multi-dimensional polymer network is described. A supramolecular complex prepared by a method of the invention is described. A method of treatment by administering a therapeutically effective amount of a supramolecular complex of the invention is also described. Such a supramolecular complex may be used as a delivery vehicle for various therapeutic agents. | 11-13-2008 |
| 20080279955 | Pharmaceutical microparticles - Microparticles consisting of (a) a matrix with a mixture of (a1) at least one hydrophobic, biologically degradable polymer and (a2) optionally at least one water-soluble polymer, (b) a pharmaceutical active ingredient distributed in the matrix, and (c) in addition at least one water-insoluble, surface-active substance from the group of lecithins and phospholipids, distributed in the matrix, and a three-phase emulsion process for their preparation. | 11-13-2008 |
| 20080286375 | Method for Preparing Sustained-Release Microparticles Comprising Sucrose Acetate Isobutyrate - A sustained release microparticles which is capable of releasing a protein drug continuously over a long period of time without initial burst release of the drug can be simply prepared by a method including the steps of a) dissolving a protein drug in an aqueous solution to obtain a water phase; b) dissolving sucrose acetate isobutyrate (SAIB) and a biodegradable polymer in an organic solvent to obtain an oil phase; c) adding the water phase obtained in step a) to the oil phase obtained in step b) to form a primary emulsion; and d) adding the primary emulsion to an external aqueous continuous phase to form a secondary emulsion and recovering the solid product formed in the secondary emulsion. | 11-20-2008 |
| 20080286376 | DRY HEMOSTATIC COMPOSITIONS AND METHODS FOR THEIR PREPARATION - Dry cross-linked gelatin compositions are prepared that rapidly re-hydrate to produce gelatin hydrogels suitable as hemostatic sealants. Gelatin is cross-linked in the presence of certain re-hydration aids, such as polyethylene glycol, polyvinylprovidone, and dextran, in order to produce a dry cross-linked gelatin powder. The use of the re-hydration aids has been found to substantially increase the re-hydration rate in the presence of an aqueous re-hydration medium, typically thrombin-containing saline. | 11-20-2008 |
| 20080292713 | Respirable Powders - A spray dried dispersible powdered composition suitable for inhalation by a human subject, which composition comprises: a) at least one active agent suitable for treating a condition in said subject by inhalation; b) a hydrophobic amino acid; and c) a pharmaceutically acceptable biodegradable polymer. | 11-27-2008 |
| 20080299210 | STABLE NANOSIZED AMORPHOUS DRUG - Disclosed is a population of nanoparticles, together with methods of making a population of nanoparticles, wherein one or more of the nanoparticles includes: an amorphous drug core having an effective diameter less than or equal to about 2.0 microns, wherein the amorphous drug core is substantially free of dopant, and wherein the amorphous drug core includes a drug with properties that satisfy the following relationships: a glass transition temperature greater than or equal to about 50 Deg. C., a glass forming ability less than or equal to about 0.85; and water solubility at 25 Deg. C. less than or equal to about 1 mg/ml; and at least one stabilizer adsorbed on a surface of the amorphous drug core; and wherein the population of nanoparticles exhibits greater than about six months amorphous stability. | 12-04-2008 |
| 20080299211 | FEXOFENADINE SUSPENSION FORMULATION - The present invention is directed to an aqueous pharmaceutical suspension of fexofenadine zwitterionic dihydrate Form I. | 12-04-2008 |
| 20080317864 | Chitosan and Heparin Nanoparticles - The invention is aimed at nanoparticulate systems for the controlled release of heparin. It is specifically aimed at nanoparticulate systems comprising chitosan, heparin and optionally a polyoxyethylenated derivative, and which are ionically cross-linked, as well as being aimed at processes for obtaining them. | 12-25-2008 |
| 20080317865 | Quench liquids and washing systems for production of microparticles - The present invention provides coacervation methods forming compositions for the sustained release water soluble active agents, including biologically active polypeptides. The invention further relates to the discovery of improved non-aqueous quench liquids and washing systems, which enable a reduction in the amount and concentration of hardening agents such as heptane used to produce microparticles, while providing acceptable product yields and residual solvent levels. | 12-25-2008 |
| 20080317866 | COLLAGEN-BASED MICROSPHERES AND METHODS OF PREPARATION AND USES THEREOF - A method of manufacture of ECM microparticles incorporating bioactive molecules for drug delivery has been developed, using a modified emulsification method or a water-in-oil-phase-separation method. The microspheres are photochemically crosslinked to control the release of the bioactive molecules for better drug delivery usage without compromising the biocompatibility of the crosslinked structures. The method uses mild fabrication conditions and simple processes, no toxic chemical crosslinking reagent, which may cause cytotoxicity and calcification after implantation, no organic solvents, which may reduce drug availability and bioactivity, and no vigorous stirring action, which may fragmentize material with poor shape and mechanical stability and thus destabilize the emulsion. The resulting microparticles or microspheres are of controlled size, controlled release, highly biocompatible, and useful for drug delivery as well as cell culture. | 12-25-2008 |
| 20090011036 | Drug containing hollow protein nanoparticles of particle-forming protein, fused with disease-treating target-cell-substance - The subject invention provides a disease-treating drug that uses hollow protein nanoparticles to specifically act on a target cell or tissue. The present invention allows a protein drug to be effectively capsulated in the particles. The invention also provides a therapeutic method using such a drug. The drug according to the present invention is capable of recognizing a specific cell, such as hepatocytes, and manufactured by fusing a disease-treating substance for a target cell (for example, interferon, hepatocyte growth factor etc.) with hollow nanoparticles of a particle-forming protein (for example, hepatitis B virus surface-antigen protein). | 01-08-2009 |
| 20090011037 | Sulfoalkyl Ether Cyclodextrin Compositions and Methods of Preparation Thereof - A particulate SAE-CD composition is provided. The SAE-CD composition has an advantageous combination of physical properties not found in known solid forms of SAE-CD. In particular, the SAE-CD composition possesses an advantageous physicochemical and morphological property profile such that it can be tailored to particular uses. The SAE-CD composition of the invention has improved flow and dissolution performance as compared to known compositions of SAE-CD. | 01-08-2009 |
| 20090028956 | Polypeptide microparticles - The invention provides polypeptide microparticles and methods for the preparation thereof using a nucleating agent. | 01-29-2009 |
| 20090047356 | TISSUE FACTOR COMPOSITIONS AND METHODS - Tissue Factor (natural or recombinant truncated) can be incorporated into stable, soluble nanoscale particles so that activity is maintained. These particles can be used as a reagent in prothrombin clotting time assays or they can be used in therapeutic compositions for use in humans or animals. Therapeutic settings can include supplementation in the case of a genetic deficiency, uncontrolled bleeding, surgical incisions or seepage, thrombocytopenia, soft tissue trauma or other trauma, to effect tumor regression or to inhibit tumor growth. | 02-19-2009 |
| 20090053317 | MICROPARTICULATE SYSTEMS FOR THE ORAL ADMINISTRATION OF BIOLOGICALLY ACTIVE SUBSTANCES - The present invention relates to gastroresistant and enterosoluble microparticulate systems for the encapsulation of biologically active substances selected from: flavonoids, vitamins, antioxidants, immunostimulants, starchy and non-starchy polysaccharides, probiotics, prebiotics, intestinal trophism regulators, oligoelements, enzymes and bioactive peptides. Such microparticulate systems allow the administration of the aforementioned nutraceutic substances to animals such as porcines, bovines, caprines, ovines, equids, canids, felines, camelids, lagomorphs, rodents, fowl, and other mammals, including humans, fish and crustaceans, increasing the bioavailability. | 02-26-2009 |
| 20090061008 | FIBER/GRANULE COMPLEX FOR TREATMENT OF THE GI TRACT - A method for treating a gastrointestinal (GI) tract including providing a fiber/granule complex made of non-absorbable fibers having granules attached thereto, and ingesting the fiber/granule complex orally, wherein the fiber/granule complex treats materials in the GI tract as it passes through the GI tract, the fiber/granule complex not being substantially absorbed by the GI tract. | 03-05-2009 |
| 20090074875 | Nanoparticulate compositions having lysozyme as a surface stabilizer - The present invention is directed to nanoparticulate active agent compositions comprising lysozyme as a surface stabilizer. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate active agent composition of the invention and methods of making and using such nanoparticulate and pharmaceutical compositions. | 03-19-2009 |
| 20090081308 | ANHDYROUS LACTOSE AGGLOMERATES AND THE PREPARATION THEREOF - The invention relates to a process for the preparation of anhydrous lactose agglomerates, said process comprising (i) subjecting essentially anhydrous lactose primary particles comprising at least 60 wt % crystalline-lactose in a granulator to a wet granulation step at a temperature in the range of 30-100° C. using a binder solution, wherein the granulation mass is subjected to drying for at least part of the granulation step, and (ii) after-drying the granulation mass. The anhydrous lactose agglomerates thus produced comprise at least 50 wt %-lactose crystallites and have a total water content in the range of 0-1.0 wt %, which is required according to the standards laid down by the Pharmacopoeia for anhydrous lactose excipients. These agglomerates combine have excellent compactibility and flowability properties and are particularly useful as excipient in moisture-sensitive applications. | 03-26-2009 |
| 20090087494 | Methods and Compositions for Targeted Delivery of Therapeutic Agents - Compositions and methods for targeted delivery of therapeutic agents, and particularly for mucosal, oral, nasal, or parenteral delivery of therapeutic agents. The compositions comprise carrier particles containing or encapsulating a therapeutic agent or agents, which have been modified on their surface to contain one or more targeting moieties that enable the enhanced uptake and transport of the therapeutic agent via receptor-mediated processes such as endocytosis or transcytosis. | 04-02-2009 |
| 20090092674 | FLOWABLE WOUND MATRIX AND ITS PREPARATION AND USE - This invention relates to a flowable collagen/glycosaminoglycan (GAG) material including particles of collagen/GAG matrix that, when hydrated, can be effectively delivered to wounds having varying depths and geometries. The flowable collagen/GAG matrix allows a more intimate contact between the wound matrix and the wound bed, and provides a structural framework that serves as a scaffold for cell ingrowth. | 04-09-2009 |
| 20090098211 | SOLID DOSAGE FORMS - Pharmaceutical dosage forms comprising tadalafil are described. Preferred dosage forms are bioequivalent to Cialis® notwithstanding a large particle size. | 04-16-2009 |
| 20090110742 | Long-acting colloidal insulin formulation and its preparation - The invention relates to injectable long-acting insulin formulations for the treatment of types I and II diabetes in humans and animals. | 04-30-2009 |
| 20090110743 | Porous beta-tricalcium phosphate granules and methods for producing same - A porous β-tricalcium phosphate material for bone implantation is provided. The multiple pores in the porous TCP body are separate discrete voids and are not interconnected. The pore size diameter is in the range of 20-500 μm, preferably 50-125 μm. The porous β-TCP material provides a carrier matrix for bioactive agents and can form a moldable putty composition upon the addition of a binder. Preferably, the bioactive agent is encapsulated in a biodegradable agent. The invention provides a kit and an implant device comprising the porous β-TCP, and a bioactive agent and a binder. The invention also provides an implantable prosthetic device comprising a prosthetic implant having a surface region, a porous β-TCP material disposed on the surface region and optionally comprising at least a bioactive agent or a binder. Methods of producing the porous β-TCP material and inducing bone formation are also provided. | 04-30-2009 |
| 20090136584 | TOOTHPASTE - A toothpaste filled in a container which has two chambers and is capable of simultaneously discharging two different compositions filled respectively in the two chambers when the main body of the container is pressed, wherein a ratio of a storage modulus G | 05-28-2009 |
| 20090142407 | Solid peptide preparations for inhalation and their preparation - The invention relates to solid pharmaceutical preparations, in particular for inhalatory administration in mammals, their preparation and their use such as, for example, in powder inhalers. | 06-04-2009 |
| 20090148534 | Process for producing water-soluble hyaluronic acid modification - The present invention provides a water-soluble modified HA practically used as a drug carrier and a production method thereof. The present invention provides: a water-soluble modified hyaluronic acid, the residence time in blood of which is elongated to a practical level, which is produced by introducing a substituent into the carboxy group of the glucuronic acid of hyaluronic acid or a derivative thereof, via an amide bond, at a lower limit of an introduction rate of 5 mole % or more, using a BOP condensing agent in an aprotic polar solvent; and a production method thereof. Moreover, by cross-linking the modified hyaluronic acid, the present invention provides a hyaluronic acid gel capable of extremely long drug sustained-release even at the same cross-linking functional group introduction rate as that of the conventionally known gel. | 06-11-2009 |
| 20090148535 | METHOD FOR TREATING CANCER USING INTERFERENCE RNA - The present application discloses acolloidal nanoparticle that includes a therapeutic nucleic acid species and a targeting protein species attached via a coating on the nanoparticle that facilitates the specific attachment of both species. | 06-11-2009 |
| 20090155373 | COSMETIC COMPOSITIONS AND METHOD WHICH IMPART A HEALTHY APPEARANCE TO SKIN - A cosmetic product and method of imparting a healthy appearance to skin is provided which includes using a composition formed with about 0.1 to about 20% by weight of the composition of beads, from about 1 to about 80% by weight of the beads of a coloring agent incorporated within a matrix of the beads, and a cosmetically acceptable carrier, the composition being delivered from a package with instructions being printed on or associated with the package indicating topical use on skin to impart a healthy appearance, and wherein the skin with the applied composition has a reflectance in the range from 510 to 600 nm, and reflectance amplitude ratios at wavelength 510/540 nm ranging from 1.10 to 1.20 and at wavelength 600/580 nm ranging from 1.35 to 1.65. | 06-18-2009 |
| 20090155374 | Nanoparticles for protein drug delivery - The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one protein drug or bioactive agent characterized with a positive surface charge and their enhanced permeability for paracellular protein drug and bioactive agent delivery. | 06-18-2009 |
| 20090169636 | Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions - Immunogenic compositions are described herein which comprise microparticles that further comprise a biodegradable polymer. The microparticle compositions also comprise a cationic polysaccharide and an immunological species selected from an antigen, an immunological adjuvant and a combination thereof. Also described are methods of making such compositions and methods of administering such compositions. Methods of modulating the release rate of immunological species from microparticles are also described. These methods comprise varying the ratio of the cationic polysaccharide relative to the biodegradable polymer within the microparticles. | 07-02-2009 |
| 20090169637 | NANOCOMPOSITE PARTICLES - Nanocomposite particles having good solubility and redispersibility in water are provided. The nanocomposite particles include a sugar material and nanoparticles containing a drug to be delivered and a biodegradable polymer, the sugar material being disaccharide, and a mass ratio of the nanoparticles to the disaccharide being within the range of from 40:60 to 60:40. | 07-02-2009 |
| 20090169638 | Inhibitors of ribonucleotide reductase subunit 2 and uses thereof - The present application relates to inhibitors of ribonucleotide reductase subunit 2 (R2), and methods and compositions related to the R2 inhibitors. In certain embodiments, the R2 inhibitors include nucleic acids, such as for example siRNAs. | 07-02-2009 |
| 20090169639 | PARTICLES FOR INJECTION AND PROCESSES FOR FORMING THE SAME - In accordance with one aspect of the invention, injectable particles are provided which comprise (a) a vinyl formal polymer, (b) a glucosamine polymer, and (c) an ionically or covalently bound agent selected from therapeutic agents, cell surface binding agents, and combinations thereof. Other aspects of the invention pertain to methods of making and using such particles. | 07-02-2009 |
| 20090169640 | COMPOSITONS FOR NASAL ADMINISTRATION OF PHARMACEUTICALS - Compositions for nasal administration, which comprise a pharmaceutical, a physiologically active peptide, or a peptide-related compound, and as the carrier thereof, crystalline cellulose with a specific particle diameter and/or partially pregelatinized starch are provided. Such compositions improve the in vivo absorption efficiency of pharmaceuticals. | 07-02-2009 |
| 20090191276 | COLLOIDOSOMES HAVING TUNABLE PROPERTIES AND METHODS FOR MAKING COLLOIDOSOMES HAVING TUNABLE PROPERTIES - Colloidosomes having tunable properties, methods for making the same, and applications thereof are described. Colloidosomes described herein are responsive to certain external stimulus to alter one or more properties of the colloidosome. Methods for making colloidosomes include forming a shell of colloidal particles on a core material where the colloidal particles and the core material have attractive interactions. | 07-30-2009 |
| 20090191277 | PROTEIN NANOPARTICLES - It is an object of the present invention to provide a highly safe composition comprising minoxidil and having high transparency due to the small particle size and high permeability into scalp and hair follicles. The present invention provides a protein nanoparticle which comprises minoxidil. | 07-30-2009 |
| 20090208584 | Solid preparation - The solid preparation of the present invention aims at providing a solid preparation superior in the stability during production and preservation even when a poorly water-soluble substance having a low melting point is contained in a large amount, and also superior in the disintegration property and release property of a poorly water-soluble substance having a low melting point, after oral administration, and is characterized by the following 1) to 3): 1) containing a poorly water-soluble substance having a low melting point, a saccharide, and a cellulose selected from a crystalline cellulose and a low-substituted hydroxypropylcellulose, 2) a saccharide/cellulose weight ratio exceeding 2, and 3) a cellulose content of not less than 5 wt %. | 08-20-2009 |
| 20090208585 | STABILISATION OF BIOLOGICAL MATERIALS - Biological materials such as vaccines can be stabilised in certain glassy materials, soluble in water. It has been proposed to form these glassy materials as a powder suspended in a non-aqueous liquid for injection into a patient. There is a problem in maintaining the suspension because the particles tend to sink to the bottom. The problem is solved by adding a blowing agent into a solution for which the glass is formed. The blowing agent decomposes as the solution evaporates thereby forming cavities in the resulting glass structure, reducing its density to match that of the liquid in which it is to be suspended. Other uses for the invention are in compositions intended for inhalation and for rapid dissolution in aqueous solutions immediately before use. | 08-20-2009 |
| 20090214666 | CHITIN MICROPARTICLES AND THEIR MEDICAL USES - The present invention relates to chitin microparticles and their medical uses, in particular in the treatment of allergy, or the treatment of conditions that would benefit from an upregulation of the cell mediated immune system, or an up-regulation of natural killer (NK) cell activity and/or the secretion of interferon-γ (IFN-γ). | 08-27-2009 |
| 20090232898 | Pharmaceutical Compositions Useful in the Treatment of Migraine - There is provided pharmaceutical compositions for the treatment of migraine comprising a pharmacologically-effective amount of a triptan or an ergot, or a pharmaceutically-acceptable salt thereof; a pharmacologically-effective amount of an antiemetic compound, or a pharmaceutically-acceptable salt thereof; a bioadhesion and/or a mucoadhesion promoting agent; and carrier particles, wherein the active ingredients are presented in particulate form upon the surfaces of the carrier particles, which carrier particles are larger in size than the particles of the active ingredients; and the bioadhesion and/or mucoadhesion promoting agent is, at least in part, presented on the surfaces of the carrier particles. | 09-17-2009 |
| 20090246287 | ANTI-ALLERGY COMPOSITIONS - The present invention relates to particles of glucans, particularly oxidized cellulosed for use in medicine. The invention further discloses pharmaceutical compositions for the treatment and/or prophylaxis of diseases or disorders associated with or mediated by allergens. | 10-01-2009 |
| 20090246288 | Taste-masking oral dosage form and method of preparing the same - The present invention provides a taste-masking oral dosage form which comprises a taste-masked microparticle and an excipient. The taste-masked microparticle comprises a taste-masked crystal containing an active pharmaceutical ingredient masked by a hydrophilic polymer and a starch. The present invention also provides a method for making the taste-masked microparticles and taste-masking oral dosage form. | 10-01-2009 |
| 20090252810 | Aryl/alkyl Succinic Anhydride-Hyaluronan Derivatives - The present invention relates to the modification of hyaluronic acid (HA) with aryl/alkyl succinic anhydrides (ASA) to produce aryl/alkyl succinic anhydride HA derivatives, to the derivatives as such, and to their applications and uses, particularly in the cosmetic and biomedical industries. The ASA-HA derivatives are expected to have interesting properties that can be used for advanced formulation (bind stronger to the skin compared to non-modified HA), possibly also in delivery systems for actives or drugs by encapsulation (nano/micro capsules) or formation of nano/micro spheres. Further, the low MW ASA-HA derivatives are expected to penetrate the skin more efficiently than non-modified HA of the same MW. | 10-08-2009 |
| 20090258079 | Biocompatible Block Copolymer, Use Thereof and Manufacturing Method Thereof - A biocompatible block copolymer having a hydrophobic segment composed of amino acid and hydroxycarboxylic acid and a hydrophilic segment composed of polyalkylene oxide, wherein the terminal not bonded to the hydrophilic segment of the hydrophobic segment is composed of an amino acid unit. | 10-15-2009 |
| 20090269413 | FLOWABLE COLLAGEN MATERIAL FOR DURAL CLOSURE - Flowable graft materials are provided which comprise collagen powder and a liquid in an amount sufficient to impart a flowable consistency to the material. The graft materials are sufficiently formable and pliable so as to provide both superior contact with and easier access to a surgical site than typical, more rigid grafts such as collagen sheets. These flowable materials may also be in a fluidized, paste-like and/or gel-like state and may be moldable and/or ejectable. The flowable collagen materials reduce and/or eliminate post implantation problems associated with other materials, e.g. synthetic dural sealants (hemostasis products), such as product swelling after application and implantation. The flowable graft materials are particularly useful as a dural graft. | 10-29-2009 |
| 20090274767 | PLANT PROTECTION GRANULATES TO BE APPLIED TO LEAF SURFACE - The present invention relates to granules for application to the leaf surface, and to a process for their preparation. The invention furthermore relates to the use of these granules for foliar penetration or the formulation of baits. | 11-05-2009 |
| 20090280187 | Oxidation-Stable Granulate Containing Unsaturated Fatty Acids - One aspect of the invention relates to a water-dispersible granulate having a mass weighted average diameter of at least 100 m, said granulate comprising: 40-90 wt. % of carbohydrates; 2-30 wt. % of lipids containing at least 1% unsaturated fatty acids by weight of the granulate and at least 30 mg/kg of a pro-oxidative metal selected from the group consisting of iron, copper and combinations thereof; wherein at least 50 wt. % of the lipids is present as non-dispersed lipids. Despite the fact that the present granulate contains a substantial amount of unsaturated fatty acids as well as a high level of iron and/or copper, said granulate is nonetheless very stable against oxidation. The granulate of the present invention is easy to manufacture by a process that does not employ emulsification or pro-oxidative conditions. The present invention also provides a process for the manufacture of the aforementioned granulate. | 11-12-2009 |
| 20090280188 | ASYMMETRIC FUNCTIONALIZATED NANOPARTICLES AND METHODS OF USE - Disclosed herein are asymmetrically functionalized nanoparticles. Further disclosed herein are methods of preparing asymmetrically functionalized nanoparticles. Asymmetrically functionalized nanoparticles can be used in various therapeutic methods. | 11-12-2009 |
| 20090285905 | SYSTEMS AND PROCESSES FOR SPRAY DRYING HYDROPHOBIC DRUGS WITH HYDROPHILIC EXCIPIENTS - Methods for preparing dry powders having hydrophobic and hydrophilic components comprise combining solutions of the components and spray drying them simultaneously in a spray dryer. The hydrophilic and hydrophobic component are separately dissolved in separate solvents and directed simultaneously through a nozzle, usually a coaxial nozzle, into the spray dryer. The method provides dry powders having relatively uniform characteristics. | 11-19-2009 |
| 20090291146 | PROCESS FOR MANUFACTURING LACTOSE - A process for producing lactose particles comprises combining a predetermined quantity of lactose seed particles to a first aqueous solution comprising a plurality of lactose particles to form a second solution, wherein the predetermined quantity of lactose seed particles is present in a well dispersed suspension and the first aqueous solution is saturated with said plurality of lactose particles; and subjecting the second solution to conditions sufficient to induce crystallization of the lactose seed particles to form a second plurality of lactose particles having a median particle size of about 25 microns to about 100 microns. | 11-26-2009 |
| 20090297620 | Anti-Tumor Agent - Titanium oxide-antibody conjugated particles are disclosed, which are provided with selective binding ability without loss of dispersibility and catalytic activity by modifying titanium oxide conjugated particles, dispersed in a water-based solvent by a water-soluble polymer, with an antibody via a linker molecule bound without changing the nature of the water-soluble polymer. The present invention is an antitumor agent, comprising titanium oxide-antibody conjugated particles, wherein a linker molecule is bound to the titanium oxide surface of the titanium oxide conjugated particles, dispersed in a water-based solvent by a water-soluble polymer, via at least one functional group selected from a group consisting of a carboxyl group, an amino group, a diol group, a salicylic acid group, and a phosphoric acid group, and wherein the titanium oxide conjugated particles are further modified with an antibody via the linker molecule. This antitumor agent is concentrated in the affected area and can be utilized as an agent for diagnosis or for treatment in combination with ultrasonic irradiation. | 12-03-2009 |
| 20090304804 | Biologic devices for hemostasis - A microscopic protein device and the method of manufacture and the use of such a device for hemostasis. The device, made with biologic material such as serum albumin from a human or animal source, is less than five micron in any one dimension and typically less than one micron in diameter. It does not have any other biological or drug molecules attached to it in vitro. However, the device has properties that allow it to capture, concentrate, carry or bind biomodifying molecules, such as coagulation factor(s), or potentially other drugs, after exposure to plasma in vitro; and possibly in vivo as well. After infusion of said device intravenously inside the body, hemostatic effects can be demonstrated. | 12-10-2009 |
| 20090304805 | COMBINATIONS AND MODES OF ADMINISTRATION OF THERAPEUTIC AGENTS AND COMBINATION THERAPY - The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents (such as an anti-VEGF antibody), or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime. | 12-10-2009 |
| 20090324731 | Method for Making Biodegradable Superabsorbent Particles - A method for making particles containing carboxyalkyl cellulose, comprising blending a carboxyalkyl cellulose and a starch in water to provide an aqueous gel; treating the aqueous gel with a crosslinking agent to provide a crosslinked gel; drying the crosslinked gel to provide a solid; comminuting the solid to provide a plurality of particles. | 12-31-2009 |
| 20100009007 | Non-covalent modification of microparticles and process of preparing same - The present disclosure is directed to surface-modified microparticles, pharmaceutical compositions thereof, and methods of making and using such particles. The surface-modified microparticles include a microparticle core, and at least one monolayer associated with the microparticle core. The monolayer comprises an amphiphilic polymer or non-ionic polymer grafted to an ionic polymer. | 01-14-2010 |
| 20100015240 | PROCESS FOR PREPARING MICROPARTICLES CONTAINING BIOACTIVE PEPTIDES - The present disclosure relates to processes for preparing microparticles comprising peptides and to microparticles prepared by such processes. Also disclosed are methods for delivering a bioactive peptide to a subject in need of treatment by the bioactive peptide. | 01-21-2010 |
| 20100021551 | PROCESS FOR PREPARING NANOPARTICLES OF CHITOSAN IN WATER PHASE - A method for preparing chitosan nanoparticles in water phase is provided. The method comprises the following steps:
| 01-28-2010 |
| 20100021552 | POLYSACCHARIDE NANOFIBERS HAVING ANTIMICROBIAL PROPERTIES - Polysaccharide nanofibers having anti-microbial properties, said nanofibers comprising an alginate and having silver nanoparticles dispersed throughout the nanofibers. | 01-28-2010 |
| 20100021553 | PHARMACEUTICAL FORMULATIONS FOR INTRANASAL ADMINISTRATION OF PROTEIN COMPRISING A CHITOSAN OR A DERIVATIVE THEREOF - There is provided a powder formulation for nasal delivery including a protein having a molecular weight of 10 kDa or greater and chitosan or a derivative thereof or a salt of chitosan or a salt of a derivative of chitosan. Preferably the protein is human growth hormone. | 01-28-2010 |
| 20100021554 | METHOD FOR PREVENTION AND TREATMENT OF REFLUX INJURY IN THE AERODIGESTIVE TRACT AND LARYNGOPHARYNX CAUSED BY PEPSIN - A method for treating or preventing disorders, diseases, and symptom of reflux, that is laryngopharyngeal reflux (LPR), in the laryngopharynx caused by pepsin comprises orally administering to the laryngopharynx of a patient an effective amount of cellulose powder. A method for treating or preventing damage to the lining membranes of at least some of the aerodigestive tract, the damage caused by pepsin, comprises coating at least some of the lining membranes with an effective amount of a cellulose powder. Upon inhalation of the powder, the powder coats the lining membranes. Upon coating the lining membranes, the powder becomes a gel. The gel prevents the pepsin from binding with the lining membranes, thereby preventing damage caused by pepsin in laryngopharyngeal reflux or in extra-esophageal reflux. | 01-28-2010 |
| 20100034896 | SELF-ASSEMBLING NANOPARTICLES COMPOSED OF TRANSMEMBRANE PEPTIDES AND THEIR APPLICATION FOR SPECIFIC INTRA-TUMOR DELIVERY OF ANTI-CANCER DRUGS - The invention provides a method of handling a hydrophobic agent, which method comprises (a) combining in an aqueous solution (i) a hydrophobic agent and (ii) an isolated peptide that is a structural analog of a transmembrane domain of an integral membrane protein, wherein one terminus of the peptide has one or more negatively charged residues, and (b) allowing the peptide to self-assemble into nanoparticles, wherein the nanoparticles comprise the hydrophobic agent. | 02-11-2010 |
| 20100047359 | Stable powder formulation containing a novel anticholinergic agent - The invention relates to a spray-dried powder formulation comprising particles that contain the following components i) to iii): i) a compound of formula 1, in which A represents a group selected from (I), (II) or (III), R and R′ each representing hydrogen or in combination form a group selected from a single bond, —CH | 02-25-2010 |
| 20100055195 | BIODEGRADABLE BMP NANOFIBER AND USES THEREOF - Described herein are compositions and methods for treating bone disorders. The compositions and methods relate to a nanofiber comprising one or more of one or more bone morphogenetic proteins, or one or more bone morphogenetic protein fragments bound to the nanofiber. | 03-04-2010 |
| 20100074961 | POLYMER MICROSPHERES/NANOSPHERES AND ENCAPSULATING THERAPEUTIC PROTEINS THEREIN - This invention is an improved process to formulate polymeric microspheres/nanospheres and encapsulate therapeutic proteins or other useful substances, and a polymer sphere apparatus. The invention is also methods of purifying protein-containing-polymeric-microspheres from unused polymer, and an apparatus therefore. | 03-25-2010 |
| 20100086613 | CHITOSAN VEHICLE AND METHOD FOR MAKING SAME - The invention relates to chitosan (CS) vehicles with chitosan nanoparticles, as well as methods for making such chitosan vehicles and for using them to carry a DNA or proteins by forming CS-DNA or CS-protein complexes. The present invention also relates to CS-DNA or CS-protein complexes being useful for transdermal delivery of DNA or protein with a low-pressure gene gun. In another aspect, the present invention also relates to CS-DNA or CS-protein complexes being useful for transcutaneous delivery of a DNA or protein with a skin patch. Further aspects of the present invention relate to methods for making CS-DNA or CS-protein complexes and for using them for diagnostic, therapeutic and biological industrial applications. | 04-08-2010 |
| 20100092572 | CHITOSAN-BASED COLLOIDAL PARTICLES FOR RNA DELIVERY - The present invention provides new colloidal particles of negative zeta potential comprising a ribonucleic acid, a chitosan and a polyanion, and compositions comprising such particles. The compositions are useful for delivery of ribonucleic acids into mammalian cells in vitro, ex vivo and in vivo. | 04-15-2010 |
| 20100112076 | Gellan-Gum Nanoparticles and Methods of Making and Using the Same - Compositions containing a reaction product of gellan gum and polyethylene glycol are disclosed. Methods of making controlled-release gellan gum nanoparticles and methods of using controlled-release gellan gum nanoparticles are also disclosed. | 05-06-2010 |
| 20100112077 | NANOPARTICLES OF PACLITAXEL AND ALBUMIN IN COMBINATION WITH BEVACIZUMAB AGAINST CANCER - The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents (such as an anti-VEGF antibody), or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime. | 05-06-2010 |
| 20100129460 | COMPOUNDS AND METHODS FOR PEPTIDE RIBONUCLEIC ACID CONDENSATE PARTICLES FOR RNA THERAPEUTICS - Compounds comprising condensed particles having diameters less than 1000 nm, wherein the particles comprise one or more double stranded ribonucleic acids (dsKNAs) and one or more peptides. The compounds, compositions and methods are useful for modulating gene expression by RNA Interference. | 05-27-2010 |
| 20100129461 | Process for Dispersing Amino Acids - A coated proteinaceous material can be produced by contacting the proteinaceous material with de-oiled phospholipids or mixtures thereof containing less than 20% triglycerides. The coating has between 0.1 and 1.5% by weight of the total proteinaceous material, of de-oiled lecithin. The proteinaceous material is hydrophobic, especially amino acids having a hydrophobicity of higher than 1.0 kJ/mol. In particular, the amino acids are leucine, isoleucine, valine, phenylalanine, tryptophan and/or methionine. The coated amino acids can be incorporated into food product and medicaments. | 05-27-2010 |
| 20100136127 | SOLID PREPARATION COMPRISING ALOGLIPTIN AND METFORMIN HYDROCHLORIDE - The present invention provides a solid preparation containing compound (I) [compound (I) is as defined in the specification] or a salt thereof, and metformin hydrochloride, which is useful as a therapeutic drug for diabetes and the like, and superior in the preservation stability. A solid preparation having a first part and a second part: a first part: a part containing compound (I) or a salt thereof and substantially free of metformin hydrochloride a second part: a part containing metformin hydrochloride and substantially free of compound (I) and a salt thereof. | 06-03-2010 |
| 20100136128 | Odor control fragrance additive - An odor control fragrant additive comprises compacted pellets or granules infiltrated with fragrant oil. Cellulosic material, activated carbon and binder are mixed together and compacted to produce compacted pellets or granules. The cellulosic material preferably is peat moss, which swells up during absorption of fragrant oil and acts as fragrant oil storage. Fragrant oil is delivered to activated carbon that has large surface area, which evaporates the fragrance oil to release steady fragrance output. Thus, the activated carbon, which evaporates fragrance provides steady release of fragrance in the surrounding environment of fragrant compacted pellets or granules for a period of several months without overpowering the environment with excess fragrance. The fragrant compacted pellets or granules may be used to suppress malodor from trashcans or litter boxes and may provide stand-alone additions to drawers and cabinets, emitting pleasant fragrance. | 06-03-2010 |
| 20100136129 | NANOPARTICLES COMPRISING A CYCLODEXTRIN AND A BIOLOGICALLY ACTIVE MOLECULE AND USES THEREOF - The invention relates to nanoparticles comprising a biodegradable polymer, a cyclodextrin or a derivative thereof, and a biologically active molecule. Said nanoparticles can associate large amounts of biologically active molecules, especially of a hydrophobic nature, and release the biologically active molecule providing sustained and constant plasma levels thereof when they are administered orally or through any other mucosa of the organism. | 06-03-2010 |
| 20100143487 | BIOCOMPATIBLE PROTEIN-BASED PARTICLES AND METHODS THEREOF - The present invention relates to biocompatible protein-based particles and their methods of preparation and use. More specifically the present invention relates protein-based particles including protein matrix, spread matrix and/or biocoacervate materials derived from one or more biocompatible purified proteins combined with one or more biocompatible solvents that are used to replace or repair tissue and/or bone in treatments for spinal disc(s), joint(s) (e.g. knee, hip, finger, ankle, elbow, shoulder . . . ) and organ(s) (e.g. bladder, lips, vagina, penis, urethra . . . ). In various embodiments of the present invention the protein-based particles may also include one or more pharmacologically active agents and/or one or more additives. | 06-10-2010 |
| 20100151036 | Multiphase drug delivery system - A two-phase drug delivery medium comprising a discontinuous phase and a solid continuous phase, the discontinuous phase comprising a plurality of droplets, each of which comprises a fluid and at least one drug dissolved or suspended within the fluid, and the continuous phase surrounding and encapsulating the discontinuous phase. | 06-17-2010 |
| 20100151037 | METHOD FOR THE PREPARATION OF NANOPARTICLES CONTAINING A POORLY WATER-SOLUBLE PHARMACEUTICALLY ACTIVE COMPOUND - The present application relates to a method for preparing nanoparticles containing a poorly water-soluble pharmaceutically acceptable compound and compositions containing such nanoparticulates. | 06-17-2010 |
| 20100151038 | GRANULAR MATERIAL FOR DOSAGE FORMS - A granular material which has a mean particle diameter of 150 to 800 micrometers; and an unsettled bulk density of 0.1 to 0.35 g/cm3 and/or a compactibility which results in a compact with a tensile strength of at least 1.7 MPa when the granular material is subjected to a compaction pressure of 266 MPa; and wherein the main component of the granular material is a cellulose derivative or an alkylene oxide homo- or copolymer or a blend thereof is useful for preparing dosage forms with a controlled release profile. | 06-17-2010 |
| 20100159021 | Small Molecule Ligands of the Integrin RGD Recognition Site and Methods of Use - Provided herein are compositions and methods for treating cancer by increasing the pro-apototic actions of small molecule ligands of integrin RGD recognition sites such as polyphenols by administering such compounds in conjunction with anti-angiogenic thyroid hormone analogs such as tetrac or triac. | 06-24-2010 |
| 20100166872 | NOVEL IMPROVED COMPOSITIONS FOR CANCER THERAPY - The present invention relates to novel and improved compositions of anticancer drugs, preferably taxanes, such as paclitaxel and docetaxel, their derivatives or their analogues, methods of manufacturing these compositions and methods of fractionating the particles in particular size range and methods of treating cancer patients with these compositions, which provide reduced chemotherapy-induced side-effects especially reduced chemotherapy-induced-alopecia. The composition is such that there is substantially no free drug in the said composition. | 07-01-2010 |
| 20100166873 | Eutectic-Based Self-Nanoemulsified Drug Delivery System - A eutectic-based self-nanoemulsified drug delivery system (SNEDDS) is formulated from polyoxyl 35 castor oil (Cremophor), medium chain mono- and diglycerides (capmul), essential oils, and a pharmacologically effective drug. The preferred pharmacologically effective drug is a poorly water soluble drug, such as ubiquinone (CoQ | 07-01-2010 |
| 20100166874 | Technology for Preparation of Macromolecular Microspheres - Microspheres are produced by contacting an aqueous solution of a protein or other macromolecule with an organic solvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals of defined dimensions. | 07-01-2010 |
| 20100166875 | COLOURING COMPOSITION COMPRISING STARCH DERIVATIVES AS A HYDROCOLLOID - The present invention relates to a colouring composition to be used in the manufacture of food and pharmaceutical products. | 07-01-2010 |
| 20100178354 | Remedy - It is intended to provide a remedy for diseases caused by macrophages with dysfunction or mediated by macrophages. Namely, a remedy which activates the phagocytic capacity of macrophages and thus is efficiently incorporated into the macrophages due to the vigorous phagocytosis. As a result, the macrophages with dysfunction are normalized, macrophages infected with a pathogen are exterminated or a pathogen in the infected macrophages is exterminated. | 07-15-2010 |
| 20100183731 | NANOPARTICLES COMPRISING DRUG, A NON-IONIZABLE CELLULOSIC POLYMER AND TOCOPHERYL POLYETHYLENE GLOCOL SUCCINATE - A pharmaceutical composition comprises nanoparticles comprising a poorly water soluble drug, a non-ionizable cellulosic polymer, and TPGS. | 07-22-2010 |
| 20100189801 | Drug Delivery Systems and Use Thereof - The invention provides a microsphere formulation for the sustained delivery of an aptamer, for example, an anti-Vascular Endothelial Growth Factor aptamer, to a preselected locus in a mammal, such as the eye. In addition, the invention provides methods for making such formulations, and methods of using such formulations to deliver an aptamer to a preselected locus in a mammal. In particular, the invention provides a method for delivering the aptamer to an eye for the treatment of an ocular disorder, for example, age-related macular degeneration. | 07-29-2010 |
| 20100215760 | INTRINSCIALLY FLUORESCENT CARBON NANOSPHERES AND A PROCESS THEREOF - The present invention provides solution to the problem involved in delivery of active molecules to nucleus. More particularly, the invention provides intrinsically fluorescent and inherently surface functionalized carbon nanospheres which are non-toxic. Also, these carbon nanospheres [CSP] were adsorbed with CTPB [CSP-CTPB] and the adsorbed CSP-CTPB are permeable to cells with nuclear targeting ability. In addition, the present invention provides a composition, a process to prepare the composition comprising CSP with adsorbed active/therapeutic molecules. Further, the instant invention provides a method for delivering active molecules inside a cell nucleus. | 08-26-2010 |
| 20100221352 | PHARMACEUTICAL COMPOSITION FOR THE ONCE-A-DAY ORAL ADMINISTRATION OF TROSPIUM CHLORIDE - A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (C | 09-02-2010 |
| 20100221353 | Pharmaceutical Composition For Once-A-Day Administration of Trospium Chloride - A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (C | 09-02-2010 |
| 20100221354 | PHARMACEUTICAL COMPOSITION FOR ONCE-A-DAY ORAL ADMINISTRATION OF TROSPIUM CHLORIDE - A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (C | 09-02-2010 |
| 20100221355 | PHARMACEUTICAL COMPOSITION FOR ONCE-A-DAY ORAL ADMINISTRATION OF TROSPIUM CHLORIDE - A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (C | 09-02-2010 |
| 20100221356 | PHARMACEUTICAL COMPOSITION FOR ONCE A DAY ADMINISTRATION OF TROSPIUM CHLORIDE - A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (C | 09-02-2010 |
| 20100221357 | DRUG DELIVERY PRODUCT AND METHODS - The present invention provides a particulate delivery system comprising an extracted yeast cell wall comprising beta-glucan, a payload molecule and a payload trapping molecule. The invention further provides methods of making and methods of using the particulate delivery system. | 09-02-2010 |
| 20100226996 | COMPOSITIONS AND METHODS OF DELIVERY OF PHARMACOLOGICAL AGENTS - The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. The human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The invention also provides methods for reducing one or more side effects of administration of the pharmaceutical composition, methods for inhibiting microbial growth and oxidation in the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell. | 09-09-2010 |
| 20100233279 | Compositions And Methods Comprising Analogues Of Radicicol A - Disclosed are novel analogues of the natural product radicicol A of formulae I, .Ia, pi, Ha, lib and HI, pharmaceutical compositions comprising the compounds. The compounds of the invention are kinase and phosphatase inhibitors and find utility in the treatment or prevention of kinase and phosphatase-mediated disorders. Also provided are uses and methods for the treatment or prevention of kinase- and phosphatase-mediated disorders and synthetic processes for the preparation of the compounds. | 09-16-2010 |
| 20100239683 | SUSTAINED RELEASE OF MICROCRYSTALLINE PEPTIDE SUSPENSIONS - The invention relates to a fluid, milky microcrystalline aqueous suspension of a peptide or peptidomimetic and a counter-ion of a strong proton donor in water, wherein the peptide or peptidomimetic and counter-ion are present in amounts and at a molar ratio sufficient to form the suspension upon mixing and without formation of a gel. The invention also relates to lyophilized compositions that include a dried suspension, methods of making the lyophilized composition, methods of preparing the suspension, and sustained release formulations prepared by the methods. | 09-23-2010 |
| 20100247664 | METHOD OF PREVENTING OR TREATING METABOLIC SYNDROME - Water-insoluble cellulose derivatives such as ethyl cellulose can be used to treat or prevent metabolic syndrome and/or one of the abnormalities of metabolic syndrome. | 09-30-2010 |
| 20100247665 | Spherical Particle and Method for Producing the Same - A spherical particle of the present invention contains a sugar alcohol and a crystalline cellulose and/or powdered cellulose, wherein the mass ratio between the sugar alcohol and the crystalline cellulose and/or powdered cellulose is within a range from 50:50 to 90:10, the particle size is within a range from 75 to 250 μm, the sphericity is not less than 0.8, and the bulk density is not less than 0.6 g/ml. Further, a method for producing the spherical particle of the present invention includes a granulation step of rolling a sugar alcohol having an average particle size of not more than 40 μm and a crystalline cellulose and/or powdered cellulose having an average particle size of not more than 50 μm while spraying a liquid thereon. | 09-30-2010 |
| 20100255111 | Intraperitoneal Delivery of Genetically Engineered Mesenchymal Stem Cells - A method of expressing at least one protein in an animal by intraperitoneal administration of mesenchymal stem cells (or genetically engineered mesenchymal stem cells) with at least one polynucleotide encoding at least one protein. The method may be employed, for example, in treating lysosomal storage disorders, such as Fabry Disease, or arthritic disorders, or hemophilia, or diabetes. | 10-07-2010 |
| 20100260860 | Methods for Treating Vasomotor Symptoms in Castrated Prostatic Cancer Patients with Low Dose Cyproterone Acetate - The present invention is directed to methods of treating vasomotor symptoms in castrated prostatic cancer patients in need of treatment, comprising administering about 15 mg or less of cyproterone acetate per day to the patients. The present invention is further directed to dosage forms comprising about 1 mg to about 15 mg of cyproterone acetate and a package comprising a plurality of dosage forms comprising about 1 mg to about 15 mg of cyproterone acetate. | 10-14-2010 |
| 20100278929 | ANTIBODY FORMULATIONS HAVING OPTIMIZED AGGREGATION AND FRAGMENTATION PROFILES - The present invention provides methods of optimizing the production and purification of antibody formulations that immunospecifically bind to antigens of interest and are suitable for parenteral administration to a subject, which formulations exhibit increased stability due to reduced degradation and aggregation of the antibody component on long term storage. Such methods provide formulations that offer multiple advantages over formulations produced by non-optimized methods including less stringent or more readily available transportation/storage conditions, and less frequent dosing or smaller dosage amounts in the therapeutic, prophylactic and diagnostic use of such formulations. The invention further provides methods of utilizing the formulations of the present invention. | 11-04-2010 |
| 20100278930 | ORAL CAVITY DISINTEGRATING TABLET AND METHOD OF PRODUCING THE SAME - The invention provides an orally disintegrating tablet containing (a) one or more saccharides or sugar alcohols selected from the group consisting of mannitol, lactose, xylitol, sucrose, erythritol and glucose and (b) low substituted hydroxypropylcellulose and substantially free of a starch disintegrant, which tablet is produced by steps of granulating a composition containing the above-mentioned components (a) and (b) by an agitation granulation method, and compression-molding the obtained granulation product. The invention also provides a method of producing an orally disintegrating tablet substantially free of a starch disintegrant, including steps of granulating a composition containing the above-mentioned components by an agitation granulation method, and compression-molding the obtained granulation product. | 11-04-2010 |
| 20100285143 | ORALLY ADMINISTERABLE SOLID PHARMACEUTICAL COMPOSITION AND A PROCESS THEREOF - The invention relates to improvised pharmaceutical compositions permitting ingestion via oral delivery of proteins/peptides or their conjugates, and/or cation-insulin conjugate complexes demonstrating desirable pharmacokinetic profiles and potency in efficacy models of diabetes in dogs and humans. A preferred formulation comprises 0.01%-20% w/w of insulin, insulin compound conjugates and/or cation insulin conjugates, 10%-60% w/w of one or more fatty acid components selected from saturated or unsaturated C4-C12 fatty acids and/or salts of such fatty acids and additionally contains optimal amounts of other pharmaceutically suitable polymer excipients which permit improved solubility, dissolution rate and effective bioavailability of poorly water soluble compositions and consistent in-vivo release profiles upon scalability during manufacture. A further aspect of the invention features the process of preparing the aforesaid formulations. | 11-11-2010 |
| 20100297249 | ENHANCEMENT OF THE EFFICACY OF THERAPEUTIC PROTEINS - The invention provides a formulation for the administration of at least one therapeutic mammalian protein to a mammal, and for enhancing the absorption, distribution and release of the at least one therapeutic mammalian protein in or on the mammal, the formulation consisting of at least one therapeutic mammalian protein in a micro-emulsion which micro-emulsion is constituted by a dispersion of vesicles or microsponges of a fatty acid based component in an aqueous or other pharmacologically acceptable earner in which nitrous oxide is dissolved, the fatty acid based component comprising at least one long chain fatty acid based substance selected from the group consisting of free fatty acids and derivatives of free fatty acids It further provides a method of the effective delivery of at least one therapeutic mammalian protein to a mammal and for enhancing the therapeutic efficacy of such at least one therapeutic mammalian protein, the method comprising the step of administering the at least one therapeutic mammalian protein to the mammal in such a formulation | 11-25-2010 |
| 20100303921 | Pharmaceutical Compositions Comprising Cereal Beta (1-3) Beta (1-4) Glucan - The present invention relates to pharmaceutical compositions comprising a β (1-3) β (1-4) glucan and a pharmaceutically active agent or a botanical extract. A method to extract and purify cereal β-glucan is also described. The high purity of the cereal β-glucan obtained according to the present invention allows for the preparation of clear, colourless viscous liquid preparations. These liquid preparations are stable to gelling effects when kept at ambient temperatures and low ash concentrations, and can be used to prepare the pharmaceutical compositions of the present invention. | 12-02-2010 |
| 20100330190 | IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF - Embodiments of the disclosure encompass compositions and methods for generating immune responses in an animal or human host. Embodiments of the compositions encompass proteins derived from the surface proteins of bacteria and protozoa, and in particular the flagellum component flagellin, and which have adjunctival properties when administered in conjunction with an immunogen. Embodiments of the compositions of the disclosure are modified to incorporate a heterologous transmembrane-cytoplasmic domain allowing the peptides to be incorporated into virus-like particles. Embodiments of the methods of generating an immunological response in an animal or human comprise exposing the immune system of an animal or human host to an immunogen and a virus-like particle comprising an adjuvant polypeptide including a host cell Toll-like receptor ligand polypeptide having a transmembrane-cytoplasmic tail polypeptide, and a heterologous signal peptide. | 12-30-2010 |
| 20100330191 | DIAMINOOXIDASE-CONTAINING PHARMACEUTICAL COMPOSITIONS - The present invention relates to pharmaceutical compositions, food supplement compositions and cosmetic compositions comprising diaminooxidase, and to the use thereof. | 12-30-2010 |
| 20110003007 | MICROPARTICLE AND PHARMACEUTICAL COMPOSITION THEREOF - A microparticle includes an agglomerate of a hydrophilic active substance containing particle, which particle includes an amphiphilic polymer composed of a hydrophobic segment of poly (hydroxy acid) and a hydrophilic segment of polysaccharides or polyethylene glycol, and a hydrophilic active substance. It is characterized by an efficient inclusion of the hydrophilic active substance, and a release of the hydrophilic active substance at an appropriate speed in the human body, and is hence very useful as a DDS pharmaceutical preparation. | 01-06-2011 |
| 20110008452 | MEDICINAL AGENT FOR TREATING FATNESS, DIABETES, AND DISEASES ASSOCIATED WITH IMPAIRED GLUCOSE TOLERANCE - The inventive medicinal agent comprises antibodies against beta-subunit of insulin receptor in an activated form produced by means of repeated serial dilution and an external action performed according to homeopathic technology. The inventive method for producing a solid medicinal formulation for perorally treating fatness, diabetes, and other diseases associated with impaired glucose tolerance, consists in mixing the effective amount of carrier, which is showered in a fluidised layer by a water-alcohol dilution of antibodies in the form active against the beta-subunit of the insulin receptor produced by combining the repeated serial dilution, thereby reducing the concentration of antibodies, and an external action according to homeopathic technology, and is dried at a temperature equal to or less than 35° C., with pharmaceutically acceptable additives and in subsequently pelleting the mixture thus obtained by means of direct dry compression. | 01-13-2011 |
| 20110008453 | Stable Corticosteroid Nanoparticulate Formulations And Methods For The Making And Use Thereof - Disclosed are stable corticosteroid nanoparticulate formulations, methods of making and therapeutic uses thereof. | 01-13-2011 |
| 20110008454 | IMMEDIATE RELEASE PHARMACEUTICAL GRANULE COMPOSITIONS AND A CONTINUOUS PROCESS FOR MAKING THEM - A pharmaceutical or veterinary granule composition in the form of a mixture consisting essentially of: (i) at least one drug classifiable as Class II or Class IV of the Biopharmaceutical Classification System, wherein said drug (i) constitutes from 0.5% to 20% by weight of the composition, and excipients, said pharmaceutical or veterinary granule composition providing a drug release of at least 70% within 10 minutes in water, (ii) a first excipient being a maltodextrin representing from 40% by weight to 80% by weight of said composition, (iii) a wetting amount of a second excipient being a polyethylene glycol having a weight number molecular weight between 300 and 5,000, said second excipient comprising a solid fraction and a liquid fraction, and representing from 15% to 40% by weight of said composition, and optionally one or more pharmaceutically acceptable fillers selected from the group consisting of hydrocolloids, glidants, lubricants, surfactants and diluents, wherein the weight ratio of said first excipient (ii) to said second excipient (iii) is in a range from 1:1 to 5:1. | 01-13-2011 |
| 20110008455 | Crosslinked Protein Nanocrystals, Crosslinked Protein Nanoaggregates and Method of Preparation Thereof - This invention relates to crosslinked protein nanoparticles and a method for producing the same. The method comprises the preparation and nanonization (i.e., size reduction to the nanoscale) of protein nanoparticle precursor materials—i.e., crosslinked proteins of the micron or greater size—via mechanical or hydrodynamic shear, mechanical crushing, sonic cavitation and/or hydrodynamic cavitation. | 01-13-2011 |
| 20110020457 | POLYMER-SURFACTANT NANOPARTICLES FOR SUSTAINED RELEASE OF COMPOUNDS - A polymer-surfactant nanoparticle formulation, using the anionic surfactant aerosol OT (AOT) and polysaccharide polymer alginate, is used for sustained release of water-soluble drugs. The AOT-alginate nanoparticles are suitable for encapsulating doxorubicin, verapamil and clonidine, as well as therapeutic agents effective against dermal conditions such as psoriasis. The nanoparticles are also suitable for encapsulating photo-activated compounds such as methylene blue for use in photo-dynamic therapy of cancer and other diseases, and for treating tumor cells that exhibit resistance to at least one chemotherapeutic drug. | 01-27-2011 |
| 20110020458 | SUSTAINED-RELEASE COMPOSITION OF DRUGS ENCAPSULATED IN MICROPARTICLES OF HYALURONIC ACID - A sustained-release drug composition consisting essentially of microparticles of hyaluronic acid having a high molecular weight or an inorganic salt thereof and a protein or peptide drug encased in said microparticles, wherein the average size of said microparticles ranges from 0.1 to 40 μm. | 01-27-2011 |
| 20110027376 | Hollow Multi-Layered Microspheres for Delivery of Hydrophilic Active Compounds - The present invention refers to a method of synthesizing a multi-walled microsphere comprising at least one hydrophilic active compound as well as to a multi-walled microsphere obtained by the method of the present invention. The present invention further refers pharmaceutical compositions including multi-walled microspheres of the present invention. | 02-03-2011 |
| 20110027377 | IMMEDIATE RELEASE PHARMACEUTICAL GRANULE COMPOSITIONS AND A CONTINUOUS PROCESS FOR MAKING THEM - A pharmaceutical or veterinary granule composition in the form of a mixture consisting essentially of: (i) at least one drug classifiable as Class II or Class IV of the Biopharmaceutical Classification System, wherein said drug (i) constitutes from above about 20% to 50% by weight of the composition, said pharmaceutical or veterinary granule composition providing a drug release of at least 70% within 10 minutes in water, (ii) a first excipient being a maltodextrin representing from 40% by weight to 85% by weight of said composition, (iii) a wetting amount of a second excipient being a polyethylene glycol having a weight number molecular weight between 300 and 5,000, said second excipient comprising a solid fraction and a liquid fraction, and representing from 15% to 40% by weight of said composition, and optionally one or more pharma-ceutically acceptable fillers selected from the group consisting of hydrocolloids, glidants, lubricants, surfactants and diluents, wherein the weight ratio of said first excipient (ii) to said second excipient (iii) is in a range from 1:1 to 5:1. | 02-03-2011 |
| 20110027378 | PROCESS OF MAKING FLOWABLE HEMOSTATIC COMPOSITIONS AND DEVICES CONTAINING SUCH COMPOSITIONS - The present invention includes both sterilized and unsterilized hemostatic compositions that contain a continuous, biocompatible liquid phase having a solid phase of particles of a biocompatible polymer suitable for use in hemostasis and which is substantially insoluble in the liquid phase, and a discontinuous, biocompatible gaseous phase, each of which is substantially homogenously dispersed throughout the continuous liquid phase, methods for making such compositions, medical devices that contain sterilized hemostatic compositions disposed therein and methods of making such devices. | 02-03-2011 |
| 20110033547 | DEHYDRATED CHITOSAN NANOPARTICLES - The present invention relates to dehydrated nanoparticles comprising chitosan and a nucleic acid. Preferably, the nucleic acid is a siRNA. Dehydrated nanoparticles of the invention have improved storage characteristics. The particles may be used in screening methods, e.g. where they have been dried onto a solid support, such as the surface of a culture well. The nanoparticles may also be dried onto implants for tissue engineering scaffolds, where they enable transfection of cells growing on the scaffold. Moreover, the particles have therapeutic relevance. | 02-10-2011 |
| 20110033548 | DEGRADABLE CROSSLINKED AMINATED DEXTRAN MICROSPHERES AND METHODS OF USE - Degradable, crosslinked aminated dextran microspheres are described. The microspheres contain aminated dextran crosslinked with a crosslinking agent having two or more functional groups that are capable of reacting with the primary amine groups of the aminated dextran to form covalent bonds. The degradable, crosslinked aminated dextran microspheres may be useful for temporary therapeutic embolization and drug delivery. | 02-10-2011 |
| 20110033549 | Stabilisation of Proteins - A dry composition for use in therapy or diagnosis, obtainable by drying an aqueous composition comprising a protein and one or more displacement buffers, wherein the pH of the aqueous composition is such that the protein is stable, wherein the or each displacement buffer has a pKa that is at least 1 unit greater or less than the pH of the aqueous composition, and wherein the aqueous composition is substantially free of a conventional buffer having a pKa that is within one pH unit of the pH of the aqueous composition. | 02-10-2011 |
| 20110033550 | NANOPARTICLE CARRIERS FOR DRUG ADMINISTRATION AND PROCESS FOR PRODUCING SAME - The invention provides a process for the production of nanoparticle carriers for drug delivery, said nanoparticles being produced by preparing a double emulsion of water-oil-water including one or more polymer which forms the basis of the nanoparticle carrier, blending the drug to be delivered into one of the emulsion phases, doping either the oil-phase or the outer-water phase with a carbohydrate, and spray drying the emulsion to form nanoparticles of a narrow particle size distribution of 100 nm to 1000 nm, which nanoparticles are substantially spherical. | 02-10-2011 |
| 20110033551 | NUCLEIC ACID MICROSPHERES, PRODUCTION AND DELIVERY THEREOF - Nucleic acids are prepared by dissolving compounds containing them in a suitable solvent or solvent system and forming microspheres from the resulting solution. The microspheres are administered to an individual as protection from conditions where delivery of nucleic acids is useful, such as in treatment of autoimmune disease. | 02-10-2011 |
| 20110033552 | APATITE/COLLAGEN COMPOSITE POWDER, FORMABLE-TO-ANY-SHAPE ARTIFICIAL BONE PASTE, AND THEIR PRODUCTION METHODS - An apatite/collagen composite powder absorbed and replaced by autogenous bone in the living body, a formable-to-any-shape artificial bone paste comprising an apatite/collagen composite powder and a binder, a method for producing an apatite/collagen composite powder by turning a suspension containing a fibrous apatite/collagen composite to liquid drops and rapidly cooling them, and a method for producing an apatite/collagen composite powder by granulating a blend comprising a fibrous apatite/collagen composite. | 02-10-2011 |
| 20110038942 | BETA-LACTOGLOBULIN-POLYSACCHARIDE NANOPARTICLES FOR HYDROPHOBIC BIOACTIVE COMPOUNDS - The present invention provides colloidally stable dispersions of nanoparticles comprising beta-lactoglobulin and a polysaccharide which are transparent when diluted in aqueous media. In particular these colloidally stable dispersions of nanoparticles are useful as delivery vehicles of hydrophobic nutraceuticals and fat-soluble vitamins, for enrichment of food products, especially of transparent beverages and other non-fat or low fat foods and drinks. The present invention further provides methods for the preparation of said colloidally stable dispersions. | 02-17-2011 |
| 20110045097 | SOLID PHARMACEUTICAL COMPOSITION COMPRISING IRBESARTAN - The present invention concerns preferably surfactant-free solid pharmaceutical formulations comprising, as an active ingredient, at least one of irbesartan and pharmaceutically acceptable salts thereof, and at least one disintegrant. Preferably, the active ingredient comprises irbesartan hydrochloride. | 02-24-2011 |
| 20110052715 | NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF - Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Nanoparticle forms of thyroid hormone or thyroid hormone analogs as well as uses thereof are also disclosed. | 03-03-2011 |
| 20110052716 | Adjuvant Comprising Aluminum, Oligonucleotide and Polycation - An immunological adjuvant comprises an aluminium salt, an immunostimulatory oligonucleotide and a polycationic polymer, wherein the oligonucleotide and the polymer ideally associate with each other to form a complex. The adjuvant can be included in a composition with an immunogen e.g. to elicit an immune response that protects against a bacterial disease or a fungal disease. | 03-03-2011 |
| 20110059182 | SPRAYING DEVICE AND RELATED METHOD FOR CELL AGGREGATES AND CELL AGGREGATE SUSPENSION THEREOF - A sprayer device and related method that delivers multicellular aggregates in suspension. A purpose of the sprayer embodiment may be to deliver cells into chronic wound beds, and additional purposes of the sprayer include additional application in other cell delivery environments, such as during open-heart surgery or other surgeries where it may be desirable to treat internal organs with aggregates of stem cells. | 03-10-2011 |
| 20110059183 | WATER-INSOLUBLE MEDICINE - A method of producing water-insoluble anti-cancer drug in the form of particulates, the method including preparing a water-insoluble anti-cancer drug having at least one multiple bond in the structure, and irradiating said water-insoluble anti-cancer drug with a laser beam having a wavelength of a low absorption portion in the vicinity of the foot of an absorption curve on the long wavelength side within the absorption band until said water-insoluble anti-cancer drug is formed into particulates having an average particle diameter of 50 to 200 nm. | 03-10-2011 |
| 20110064818 | PHARMACEUTICAL COMPOSITION AND A METHOD FOR THE PRODUCTION THEREOF - The invention relates to producing medicinal agents for treating diabetes. There is proposed a method for producing a pharmaceutical composition containing insulin on a polysaccharide carrier, which involves mixing initial ingredients, wherein there is provided, for mixing, supplying positively charged chitosan sol with pH of 3.5 to 4.5 and negatively charged zinc free insulin, which is taken in the form of a colloidal solution or in the form of nanosized crystalline particles, bringing the pH of the mixed sol to a value of 5.5 to 6.5, producing a gel and dehydrating the produced gel to obtain solid particles, the size of which ranges from 10 to 100 mkm. The method makes it possible to produce a stable controlled release insulin-containing composition for peroral administration | 03-17-2011 |
| 20110064819 | ENCAPSULATION OF BIOLOGICALLY ACTIVE AGENTS - The present invention provides methods of encapsulating biologically active agents such as proteins in particulate carriers such as nanoparticles using Hip agents. Also provided are compositions comprising particulate carriers obtainable by such methods and uses of such compositions in treatment. | 03-17-2011 |
| 20110070311 | Producing a sustained-release preparation - This invention provides a production method for a solid sustained-release preparation, characterized in that a sustained-release preparation (a sustained-release preparation suspension) is freeze-dried in a freeze-drying container whose inner face is partially or totally coated with an ice layer or water-repelling base material. | 03-24-2011 |
| 20110081420 | METHOD OF FORMING PROLONGED-RELEASE INJECTABLE STEROIDS - A method of forming prolonged-release injectable steroids. The method includes providing a steroid composition, a bioabsorbable polymer and a solvent. A solution is formed from the steroid composition, the bioabsorbable polymer and the solvent. Droplets are formed from the solution. The solvent is removed from the droplets to cause the droplets to form microspheres. | 04-07-2011 |
| 20110081421 | METHODS OF REGULATING RENALASE (MONOAMINE OXIDASE C) - The present invention provides methods of using Monoamine Oxidase C (MAO-C), also known as renalase, as a therapeutic protein in its active and inactive forms. Administering inactive renalase protein to individuals with lower renalase levels can be used to provide them with an adequate pool of the protein that can be activated by the body as needed. Active renalase protein can be administered to individuals needing an immediate reduction of catecholamine levels. An inhibitor of renalase may be used to enhance adrenergic action. | 04-07-2011 |
| 20110091564 | INJECTABLE HOLLOW TISSUE FILLER - The present invention comprises a plurality of injectable hollow particulate fillers suspended in a biocompatible fluid carrier to significantly improve the clumping resistance and injectability of the composition. The hollow particulate fillers have a lower effective density and are able to suspend in the carrier without precipitation. The loss of skin volume as a result of aging, diseases, weight loss, and injury can lead to uneven skin surface (e.g. wrinkle, etc.). The uneven skin can be repaired by injecting appropriate amount of hollow fillers underneath the skin. Some cases of urinary incontinence occur when the resistance to urine flow has decreased excessively. Continence is restored by injecting the present invention to the urethra tissue to increase resistance to urine outflow. Similarly, the present invention allows for the control of gastric fluid reflux by submucosal injections of the fillers to the esophageal-gastric and gastric-pyloric junction. For patients with vesicoureteral reflux, it can be treated by injection of the present invention into patients' ureteral tissue. This invention can also be used to repair defective or inadequately functioning muscles of the anal sphincter by administering an effective amount of injectable hollow fillers into the defect or anal sinuses. | 04-21-2011 |
| 20110091565 | METHOD OF FORMING NON-IMMUNOGENIC HYDROPHOBIC PROTEIN NANOPARTICLES AND USES THEREFOR - Methods are described for producing non-immunogenic nanoparticles from protein sources by controlling the pH in a nanoprecipitation process. The nanoparticles that are produced by the disclosed methods range in diameter size from about 100 ran to about 400 nm, with a preferred diameter size of from approximately 100 nm to approximately 300 nm, thereby rendering them non-immunogenic. The invention further discloses methods for producing nanoconjugates that are suitable for a variety of therapeutic, diagnostic and other uses. | 04-21-2011 |
| 20110097417 | MELAN-A-CARRIER CONJUGATES - The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a modified virus-like particle (VLP) comprising a VLP which can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs), and particular peptides derived from MelanA linked thereto. Such CpG-VLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against MelanA peptide analogues optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself. In addition, the T cell responses against the MelanA peptide analogues are especially directed to the Th1 type. Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases. | 04-28-2011 |
| 20110097418 | COMPOSITIONS AND METHODS FOR TREATING INFLUENZA - The present application provides compositions and methods useful for treating influenza. As described herein, the compositions and methods are based on the development of peptides and peptide combinations which exhibit immunogenic properties against influenza. In some embodiments, the peptide combinations induce a protective response against multiple strains of influenza, e.g., seasonal strains of influenza or even the new pandemic influenza A (H1N1) virus of swine origin. | 04-28-2011 |
| 20110104295 | PHARMACEUTICAL COMPOSITIONS AND METHODS RELATING TO INHIBITING FIBROUS ADHESIONS OR INFLAMMATORY DISEASE USING LOW SULPHATE FUCANS - Compositions and methods involving administration of agents useful for the treatment, prevention, inhibition, etc., of inflammatory disease or fibrous adhesions using low sulphate fucans and, if desired, one or more other anti-inflammatory disease or anti-fibrous adhesion agent. | 05-05-2011 |
| 20110104296 | Endorphin Therapy Compositions and Methods - In certain embodiments, the invention provides methods of isolating and culturing neuronal stem cells from hypothalmi, methods of differentiating the neuronal cells into beta-endorphin neurons, and methods of treatment of various diseases comprising administering agents to differentiate endogenous neuronal stem cells into beta endorphin neurons. | 05-05-2011 |
| 20110111043 | PEPTIDES AND THEIR USE AS CARRIERS INTO CANCER CELLS - The use of a peptide is described as a carrier for the transport of molecules or radioisotopes into cancer cells; also described are modifications of said peptide and their use. | 05-12-2011 |
| 20110117206 | PHOSPHOPEPTIDES AND USE OF THE SAME - The present application relates to methods of providing thermodynamically stable calcium phosphate nanoclusters and uses thereof. | 05-19-2011 |
| 20110123637 | PROTAMINE/RNA NANOPARTICLES FOR IMMUNOSTIMULATION - The present invention relates to protamine/RNA nanoparticles of defined average size, a pharmaceutical composition containing said nanoparticles and to a method of producing the same. The nanoparticles of the present invention is particularly useful as an immunostimulating medicament with a precise pattern of immunostimulation different from the prior art. | 05-26-2011 |
| 20110129541 | SUSPENSION DELIVERY SYSTEM FOR THE SUSTAINED AND CONTROLLED LOCAL RELEASE OF PHARMACEUTICALS - The invention relates to a novel suspension delivery system for the sustained and controlled release of pharmaceuticals. Methods of preparation and use are also disclosed. | 06-02-2011 |
| 20110135742 | CONTROLLED RELEASE ENCAPSULATED ANTI-BACTERIAL AND ANTI-INFLAMMATORY NANOPARTICLES - This invention pertains to the formulation of nanoparticles that have intrinsic antimicrobial and anti-inflammatory activity. The nanoparticles can be impregnated with one or more therapeutic agents and thereby enhance the antimicrobial and/or anti-inflammatory activity of such agents, and also other properties that the therapeutic agents provide. | 06-09-2011 |
| 20110135743 | CARBOXYVINYL POLYMER-CONTAINING NANOPARTICLE SUSPENSIONS - The present invention generally relates to suspension compositions having a carboxyvinyl polymer such as a carbomer, a galactomannan such as guar, and a borate compound. A sparingly soluble particulate compound such as nepafenac is also included in the compositions. The sparingly soluble particulate compound has a small particle size to enhance bioavailability of the compound. | 06-09-2011 |
| 20110151014 | MICROCRYSTALLINE CELLULOSE AND CALCIUM CARBONATE COMPOSITIONS USEFUL AS RECOMPACTIBLE PHARMACEUTICAL EXCIPIENTS - Coprocessed compositions containing microcrystalline cellulose and calcium carbonate, wherein the weight ratio of microcrystalline cellulose to calcium carbonate is relatively high, are useful as excipients in the preparation of solid dosage forms containing active pharmaceutical ingredients, particularly those prepared by processes involving multiple compaction steps. Such compositions may be obtained, for example, by preparing aqueous slurries or wet masses of microcrystalline cellulose and calcium carbonate and drying such slurries or wet masses to produce particulate products. The coprocessed products exhibit improved recompactibility, as compared to coprocessed products having lower microcrystalline cellulose:calcium carbonate weight ratios or as compared to physical dry blends of the two excipients. | 06-23-2011 |
| 20110171315 | Oral recombinant helicobacter pylori vaccine and preparing method thereof - The invention relates to a recombinant protein used for immunoprophylaxis of human | 07-14-2011 |
| 20110171316 | EXPRESSION AND ASSEMBLY OF HUMAN GROUP C ROTAVIRUS-LIKE PARTICLES AND USES THEREOF - Group C rotaviruses are a cause of acute gastroenteritis in children and adults that is distinct from group A RV. However, human group C rotaviruses cannot be grown in culture, resulting in a lack of tools for detection and treatment of GrpC RV disease. Consequently, the burden of GpC RV disease has not been clearly established. Isolated recombinant human rotavirus group C virus-like particles are provided according to embodiments of the present invention along with methods of their production and use in, inter alia, detection of Grp C RV infection, diagnostic assays and immunogenic compositions. | 07-14-2011 |
| 20110182998 | MICROSPHERES USEFUL FOR THERAPEUTIC VASCULAR EMBOLIZATION - Provided herein, for example, are microspheres comprising a gelatin or gelatin substitute and a copolymer of a N-tris-hydroxymethyl methylacrylamide monomer unit, a diethylaminoethylacrylamide monomer unit and a N,N-methylene-bis-acrylamide monomer unit. Also provided are methods of producing microspheres comprising a gelatin or gelatin substitute and a copolymer of a N-tris-hydroxymethyl methylacrylamide monomer unit, a diethylaminoethylacrylamide monomer unit and a N,N-methylene-bis-acrylamide monomer unit. Further provided herein, for example, are compositions comprising the microspheres and methods of using the microspheres and compositions thereof. | 07-28-2011 |
| 20110195127 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B - The present invention provides compositions and methods for the delivery of interfering RNAs that silence APOB expression to liver cells. In particular, the nucleic acid-lipid particles provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of APOB at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art. | 08-11-2011 |
| 20110217384 | Modified Release Dosage Forms of Skeletal Muscle Relaxants - A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. At least one bead population exhibits a pre-designed sustained release profile. Such a drug delivery system is designed for once-daily oral administration to maintain an adequate plasma concentration—time profile, thereby providing relief of muscle spasm associated with painful musculoskeletal conditions over a 24 hour period. | 09-08-2011 |
| 20110229581 | RELEASABLE CATIONIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEMS - The present invention is directed to releasable cationic lipids and nanoparticle compositions for the delivery of nucleic acids and methods of modulating an expression of a target gene using the same. In particular, the invention relates to cationic lipids including an acid labile linker, and nanoparticle compositions containing the same. | 09-22-2011 |
| 20110256231 | METHOD FOR PREPARING A MICRO-PARTICLE DRUG IN HEMISPHERE-SHAPED DOSAGE FORM AND APPLICATIONS THEREOF - A method for preparing drug in hemisphere-shaped dosage form. A high molecular weight solution containing the drug is prepared, and the solution is then dropped on a base material. The interface phenomena between the solution and different base materials makes the drop of high molecular weight solution containing the drug form a hemisphere-shape. After solidifying by cross-link or evaporation, the drug in hemisphere-shaped dosage form is obtained. The advantages of the preparation method are a simple and fast process, and simple operation. Applications of the method to prepare a drug in hemisphere-shaped dosage form are also provided. | 10-20-2011 |
| 20110268809 | Nicotine-Containing Pharmaceutical Compositions - A composition intended to be employed for therapeutic purposes incorporates a source of nicotine and at least one levulinate moiety. Representative forms of nicotine include free base (e.g., as a mixture of nicotine and microcrystalline cellulose), a nicotine salt (e.g., as nicotine bitartrate) or nicotine polacrilex. The levulinate moiety can have the form of an acid (e.g., levulinic acid), a levulinate salt (e.g., sodium levulinate), or an ester of levulinic acid (e.g., methyl levulinate or ethyl levulinate). The composition can incorporate nicotine and levulinic acid in a salt form (e.g., nicotine levulinate). The composition can be composed of at least two forms of nicotine, and one of the forms of nicotine is in the form of nicotine levulinate. The composition is useful for treatment of central nervous system conditions, diseases, and disorders, and as a nicotine replacement therapy. | 11-03-2011 |
| 20110268810 | POLYMERIC MATERIALS LOADED WITH MUTAGENIC AND RECOMBINAGENIC NUCLEIC ACIDS - Polymeric microparticles are used to deliver recombinagenic or mutagenic nucleic acid molecules such as donor nucleic acid alone, or in combination with triplex-forming molecules, to induce a site-specific mutation in the target DNA. Target cells endocytose the particles, releasing the nucleic acid molecules inside of the cell, where they induce mutagenesis or recombination at a target site. The examples demonstrate that triplex forming oligonucleotides, preferably PNAs, preferably in combination with a donor nucleotide molecule, can be encapsulated into polymeric microparticles, which are delivered into cells. Results demonstrate significantly greatly levels of uptake and expression, and less cytotoxicity, as compared to direct transfer of the nucleic acid molecules into the cell by nucleofection. | 11-03-2011 |
| 20110280947 | Embolization - A particle includes a ferromagnetic material, a radiopaque material, and/or an MRI-visible material. | 11-17-2011 |
| 20110293732 | NANOPARTICLES MADE OF AMORPHOUS CELLULOSE - The present invention provides novel nanoscale cellulose particles and also a process for their production. The cellulose-based particles obtained have volume -averaged particle sizes of less than 300 nm. These nanoparticles are produced from amorphous cellulose or by amorphization of cellulose, optional subsequent hydrolysis and by input of energy into a water-containing medium after or during dispersion. | 12-01-2011 |
| 20110293733 | SELF-ASSEMBLING NANOPARTICLE DRUG DELIVERY SYSTEM - A self-assembling nanoparticle drug delivery system for the delivery of drugs including peptides, proteins, nucleic acids or synthetic chemical drugs is provided. The self-assembling nanoparticle drug delivery system described herein includes viral capsid proteins, such as Hepatitis B Virus core protein, encapsulating the drug, a lipid bi-layer envelope and targeting or facilitating molecules anchored in the lipid bilayer. A method for construction of the self-assembling nanoparticle drug delivery system is also provided. | 12-01-2011 |
| 20110300226 | PEPTIDE PARTICLE FORMULATION - A composition as disclosed is comprised of a plurality of groups of particles. The particles are comprised of a biocompatible polymer which maybe a co-polymer such as PLGA combined with a peptide of a sequence of interest, e.g. a sequence which corresponds to a sequence presented on a surface of a cell infected with a virus. A plurality of different groups of particles are provided in the formulation wherein the particles within any single group include peptides of identical amino acid sequence. The particles are sized such that they are sufficiently large so as to prevent more than the contents of a single particle from being presented to a single immune system cell. | 12-08-2011 |
| 20110305768 | QUICK-DISSOLVING ORAL THIN FILM FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS - This invention describes a quick-dissolving thin film strips comprising bioactive components encapsulated within pH-sensitive polymeric microparticles. The microparticles are embedded within the thin film and provide protection to components encapsulated within. The invention further describes methods to incorporate bioactive components encapsulated within pH-sensitive polymeric microparticles into a quick-dissolving thin film strip while maintaining the bioactivity of the contained therapeutic agents during thin film formation and microencapsulation. | 12-15-2011 |
| 20110305769 | BRANCHED CATIONIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEM - The present invention is directed to cationic lipid for the delivery of oligonucleotides and methods of modulating an expression of a targeted gene using the nanoparticle compositions. In particular, the invention relates to cholesterol and its derivatives having multiple positively charged moieties via branching spacers, and nanoparticle compositions of oligonucleotides encapsulated in a mixture of a cationic lipid, a fusogenic lipid and a PEG lipid. | 12-15-2011 |
| 20110305770 | RELEASABLE POLYMERIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEM - The present invention relates to polymer conjugated releasable lipids and nanoparticle compositions containing the same for the delivery of nucleic acids and methods of modulating gene expression using the same. In particular, this invention relates to releasable polymeric lipids containing an acid-labile linker based on a ketal or acetal-containing linker, or an imine-containing linker. | 12-15-2011 |
| 20120009268 | Modified Virus Vectors and Methods of Making and Using the Same - The present invention provides AAV capsid proteins (VP1, VP2 and/or VP3) comprising a modification in the amino acid sequence in the three-fold axis loop 4 and virus capsids and virus vectors comprising the modified AAV capsid protein. In particular embodiments, the modification comprises a substitution of one or more amino acids at amino acid positions 585 to 590 (inclusive) of the native AAV2 capsid protein sequence or the corresponding positions of other AAV capsid proteins. The invention also provides methods of administering the virus vectors and virus capsids of the invention to a cell or to a subject in vivo. | 01-12-2012 |
| 20120027866 | METHOD OF PREPARING A GRANULAR DELIVERY SYSTEM - A method of preparing a granular delivery system by creating a melt emulsion having a continuous phase and a dispersed active, wherein the continuous phase includes trehalose and a low dextrose equivalent carbohydrate that is not a hydrogenated starch hydrolysate, forcing the melt emulsion through an die or orifice to form an extrudate, cooling and granulating the extrudate to form granules of the delivery system and optionally drying the granules. The melt extrusion provides excellent viscosity and Tg characteristics for the extrusion process. | 02-02-2012 |
| 20120040010 | MICROPARTICULATED VACCINES FOR THE ORAL OR NASAL VACCINATION AND BOOSTERING OF ANIMALS INCLUDING FISH - The invention relates to a composition and a method for manufacturing semi-dry or dry particles containing a mucoadhesive polymer and a bioactive agent such as, but not limited to, an Immunogenic Substance (e.g., a vaccine), that allows the oral or nasal administration and delivery of the bioactive agent essentially unaltered to mucosal surfaces in the animal, including an aquatic animal. | 02-16-2012 |
| 20120045517 | TREATMENT OF CELIAC DISEASE WITH IgA - A process for inhibiting symptoms of a subject with celiac disease is provided that includes administration of monoclonal-, or polyclonal-, monomeric, dimeric, or polymeric IgA. Joining secretory component to the IgA limits oral administration degradation. Formulating agents are mixed with the monomeric, dimeric, or polymeric IgA to yield a dosing form of a capsule, tablet, and a suppository. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating. | 02-23-2012 |
| 20120058196 | PHARMACEUTICAL COMPOSITIONS OF DEXTRAN POLYMER DERIVATIVES AND A CARRIER MATERIAL - Pharmaceutical compositions are provided comprising (a) nanoparticles of an active agent and a dextran polymer derivative, and (b) a carrier material. | 03-08-2012 |
| 20120064169 | MULTIPLE ANTIGEN DELIVERY SYSTEM USING HEPATITIS E VIRUS-LIKE PARTICLE - This invention provides a peptide/nucleic acid composition for oral/mucosal, dual-modal activation of immune protection systems. | 03-15-2012 |
| 20120076866 | PARTICULATE PHARMACEUTICAL COMPOSITION - The present invention provides a particulate pharmaceutical composition which has improved drug encapsulation stability and is suitable for a drug delivery system. The particulate pharmaceutical composition | 03-29-2012 |
| 20120082730 | NANOPARTICULATE IN-SITU GELS AS VITREOUS HUMOR SUBSTITUTES FOR OCULAR DISEASES - The present technology provides a nanoparticulate in-situ gelling vitreous substitute, which is a liquid at room temperature to aid easy administration, such as e.g. through a small needle incision, and forms a gel within the eye, which is hydrophilic in nature, similar to the natural vitreous. The vitreous substitute formulation may include a water-soluble natural or synthetic polymer and a gelling-agent which are blended together in the presence of a cross linker, to form a gel having the properties of the vitreous humor. The process of cross linking and gelation may occur in-situ. This can be achieved by dispensing to the eye, different components of the vitreous substitute in liquid state, along with the cross linking agent. | 04-05-2012 |
| 20120082731 | Method For Removing Residual Organic Solvent From Microparticles - Disclosed herein are methods comprising suspending microparticles in a surfactant/non-polar alkane solution to remove residual solvent that is present in the microparticle. | 04-05-2012 |
| 20120082732 | MEDICINE FOR TREATMENT OF A CARCINOMA - In a method for treating a carcinoma in a patient, a medicine is administered via the blood stream of the patient that appears, to the patient's immune system, that tissue of the carcinoma is an inflammation source. The medicine employs two active components that are coupled to each other in a form allowing administration of the two active components to the carcinoma via the blood stream of the patient. A first of the active components is at least one coupling molecule that specifically tethers to a target molecule formed by cancer tissue of the carcinoma. A second of the active ingredients is at least one signal molecule typical to inflammation, or at least one originating molecule encoding such a signal molecule, that induces the immune system of the body to attack the cancer cells. | 04-05-2012 |
| 20120156305 | METHODS FOR ENHANCING GENOME STABILITY AND TELOMERE ELONGATION IN EMBRYONIC STEM CELLS - The disclosure provides methods for increasing genome stability of an embryonic stem (ES) cell or induced pluripotent stem (iPS) cell, increasing telomere length in an ES or iPS cell, or both, for example by contacting an ES or iPS cell with an agent that increases expression of Zscan4 in the cell. Methods for increasing the genome stability in a population of ES or iPS cells, increasing telomere length in a population of ES or iPS cells, or both, are provided, for example by selecting Zscan4 | 06-21-2012 |
| 20120164234 | COMPOSITIONS AND METHODS FOR SEPARATING, CHARACTERIZING AND ADMINISTERING SOLUBLE SELENOGLYCOPROTEINS - The invention relates to soluble selenium compositions and methods of production, separation and purification thereof. In particular the present invention provides methods of preparing water soluble selenoglycoproteins (e.g., via extracting selenoglycoproteins from selenium enriched yeast), methods of supplementing a selenium deficient composition via admixing water soluble selenoglycoproteins with the selenium deficient composition, compositions comprising the water soluble selenoglycoproteins and methods of administering the same. | 06-28-2012 |
| 20120207846 | Selenium Nanoparticles with Improvded Biological Effects - Novel methods for biological effective, stable amorphous and monoclinic selenium nanoparticles are disclosed. They are prepared by reacting selenium source with a reducing agent or an oxidative agent in an aqueous media at a temperature between 0-100° C. in the presence of selenium binding polymer molecules such as poly/oligopeptide acids or peptone or nucleic acids or poly/oligosaccharide or their mixtures. | 08-16-2012 |
| 20120225129 | CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS - Particles and conjugates for delivering nucleic acid agents. Compositions containing the particles, the conjugates, or both. Methods of using the particles, the conjugates, and the compositions. | 09-06-2012 |
| 20120231086 | PROTEIN MATRIX VACCINES OF IMPROVED IMMUNOGENICITY - The present invention relates to immunogenic compositions containing an antigen of interest entrapped with a crosslinked carrier protein matrix, methods of making such vaccines, and methods of vaccine administration, wherein the immunogenicity of the protein matrix, and hence its effectiveness as a vaccine, is improved by controlling or selecting the particle size of the protein matrix particles to eliminate low molecular weight particles, e.g., less than 100 nm in diameter. | 09-13-2012 |
| 20120282343 | COMPOSITIONS FOR ORAL GENE THERAPY AND METHODS OF USING SAME - The present invention provides nanoparticle compositions comprising a cationic biopolymer and at least one biologically active substance, pharmaceutical compositions comprising such nanoparticles and methods for the oral administration of biologically active molecules which are susceptible to degradation in the gastro-intestinal tract using nanoparticle. The present invention further provides compositions and methods for the oral administration of gene therapy. | 11-08-2012 |
| 20120294948 | VACCINE - The present invention is concerned with the development of a vaccine against | 11-22-2012 |
| 20130071483 | VACCINE PRODUCED USING OPTIMIZED IMMOBILIZATION ANTIGEN cDNA OF CRYPTOCARYON IRRITANS AND PRODUCING METHOD AND USE THEREOF - The present invention provides an optimized immobilization antigen cDNA sequence of | 03-21-2013 |
| 20130108704 | RECOMBINANT PROTEINS OF PARAPOXVIRUS OVIS AND PHARMACEUTICAL COMPOSITIONS THEREFROM | 05-02-2013 |
| 20130115302 | POLYSACCHARIDE MICRO-PARTICLE ENCAPSULATIN GROWTH FACTOR - A polysaccharide micro-particle encapsulating a growth factor is disclosed and shall include one or more growth factors, and a polysaccharide shell forming a space to encapsulate the growth factor by electrostatic interaction. Also, a method for manufacturing a polysaccharide micro-particle encapsulating a growth factor is disclosed, which shall include the following process: (A) providing a pH 4.6-6 polysaccharide solution and a growth factor; and (B) adding the growth factor to the polysaccharide solution, and adjusting the polysaccharide solution to a pH of 6-8 to obtain the polysaccharide micro-particle encapsulating the growth factor by electrostatic interaction. According to the polysaccharide shell structure, the growth factor can be stored for a long period of time and heal skin wounds, mucositis, and corneal ulcer effectively. | 05-09-2013 |
| 20130122105 | Methods and Compositions for Gene Therapy and GHRH Therapy - A composition and method comprising an anti-adjuvant such as DOI (an anti-inflammatory) together with any gene therapy plasmid is disclosed. A method for GHRH production in-vivo using a set of compositions and methods for use of those compositions is provided. | 05-16-2013 |
| 20130122106 | DOSAGE FORM, AND METHODS OF MAKING AND USING THE SAME, TO PRODUCE IMMUNIZATION IN ANIMALS AND HUMANS - An embodiment of the present invention features a dosage form for administering antigen to cause an immune response in an animal or human subject in the nature of a vaccine. The dosage form comprises spheres having an effective amount of antigen to create an immune response and having an average diameter of 0.01 to 10.0 microns. The spheres comprise a polymer selected from the group consisting of poly(L-lactic acid), poly(D, L-lactic acid), poly(glycolic acid) and carboxylic acid and ester derivatives thereof, poly(fumaric anhydride) and poly(sebacic anhydride) and derivatives thereof. The spheres can be lyophilized and stored as a powder prior to use. The spheres can then be reconstituted and formulated in buffers with adjuvants. | 05-16-2013 |
| 20130209569 | NOVEL FORMULATION OF DICLOFENAC - The present invention relates to methods for producing particles of diclofenac using dry milling processes as well as compositions comprising diclofenac, medicaments produced using diclofenac in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of diclofenac administered by way of said medicaments. | 08-15-2013 |
| 20130216624 | SUSTAINED-RELEASE PELLETS CONTAINING TACROLIMUS AS AN ACTIVE INGREDIENT - The present invention relates to sustained-release pellets containing tacrolimus as an active ingredient. The sustained-release pellets of the present invention have multiple layers of hydroxypropyl methylcellulose, and may control the release of drugs by specific contents of hydroxypropyl methylcellulose and Surelease™, thus rendering the dissolution rate thereof uniform and stable, and enabling the dissolution rate to be adjusted as desired. The entire process for preparing the pellets of the present invention is carried out in a single fluidized-bed granulator, and therefore the preparation process is simplified and the time required for preparation is shortened while obtaining sustained-release pellets having uniform particle size distribution and contents. The sustained-release pellets of the present invention may have medicinal effects that last up to 24 hours, and therefore may be administered just once a day, thus improving patient compliance. Therefore, the pellets of the present invention may be effectively used in an orally administered pellet formulation containing tacrolimus as an active ingredient. | 08-22-2013 |
| 20130230598 | SUSTAINED-RELEASE COMPOSITION OF DRUGS ENCAPSULATED IN MICROPARTICLES OF HYALURONIC ACID - A sustained-release drug composition consisting essentially of microparticles of hyaluronic acid having a high molecular weight or an inorganic salt thereof and a protein or peptide drug encased in said microparticles, wherein the average size of said microparticles ranges from 0.1 to 40 μm. | 09-05-2013 |
| 20130266661 | AMPHIPHILIC CYCLIC PHOSPHAZENE TRIMER, PHARMACEUTICAL FORMULATION OF HYDROPHOBIC DRUGS BY MICELLE-ENCAPSULATION USING THE AMPHIPHILIC CYCLIC PHOSPHAZENE TRIMER, AND PREPARATION METHODS THEREOF - The present invention relates to an amphiphilic cyclic phosphazene trimer which is biocompatible and a method for preparing the same. The present invention also relates to pharmaceutical formulations of hydrophobic drugs that are micelle-encapsulated by the amphiphilic cyclic phosphazene trimer and a method for preparing the same. | 10-10-2013 |
| 20130273171 | ORAL FORMULATION FOR DEXLANSOPRAZOLE - A stable formulation of dexlansoprazole for treating a digestive disorder, and methods of manufacturing the same. | 10-17-2013 |
| 20130280336 | NANOPARTICLE COMPRISING RAPAMYCIN AND ALBUMIN AS ANTICANCER AGENT - The present invention features methods for treating, stabilizing, preventing, and/or delaying cancer by administering nanoparticles that comprise rapamycin or a derivative thereof. The invention also provides compositions (e.g., unit dosage forms) comprising nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof. The invention further provides combination therapy methods of treating cancer comprising administering to an individual an effective amount of nanoparticles that comprise rapamycin or a derivative thereof and a second therapy. | 10-24-2013 |
| 20130280337 | BREAST CANCER THERAPY BASED ON HORMONE RECEPTOR STATUS WITH NANOPARTICLES COMPRISING TAXANE - The present invention relates to methods and kits for the treatment of breast cancer based on hormone receptor status of progesterone receptor and estrogen receptor comprising the administration of a taxane alone, in combination with at least one other and other therapeutic agents, as well as other treatment modalities useful in the treatment of breast cancer. In particular, the invention relates to the use of nanoparticles comprising paclitaxel and albumin (such as Abraxane®) either alone or in combination with other chemotherapeutic agents or radiation, which may be used for the treatment of breast cancer which does not express estrogen receptor and/or progesterone receptor. | 10-24-2013 |
| 20130295190 | Systems and Methods for Superdisintegrant-Based Composite Particles for Dispersion and Dissolution of Agents - The present disclosure provides improved systems and methods utilizing colloidal/ultrafine superdisintegrant-based composite particles for dispersion and/or dissolution of active pharmaceutical agents. In general, the present disclosure utilizes a surfactant-free or near surfactant-free formulation by incorporating a wet milled SDI as a dispersant in the formulation. As such, the present disclosure provides for the preparation of surfactant-free or substantially surfactant-free formulations (e.g., nano-composite micro-particle formulations) by incorporating a wet-milled superdisintegrant (SDI) as the dispersant in the formulations. The advantageous SDI particles (e.g., colloidal/ultrafine SDI particles) of the present disclosure can be used to break-up the aggregates (e.g., nanoparticle aggregates) of the active agents (e.g. poorly water-soluble drugs) in the formulations (e.g., micro-particle formulations) and enhance the recovery of the nanoparticles of active agents during aqueous re-dispersion and their dissolution rate in vitro and in vivo. | 11-07-2013 |
| 20130323314 | Novel Nanoparticles of Lactoferrin Useful for Preparing a Pharmaceutical Composition Facilitating Easy Delivery of the Drug and a Process for Preparing the Same - Novel nanoparticles of lactoferrin useful for preparing a pharmaceutical composition facilitating easy delivery of the drug contained therein wherein the sizes are in diameter in the range of 40 to 90 nanometers. | 12-05-2013 |
| 20130323315 | Microspheres Including Oxidized Cellulose - A process for forming microspheres is disclosed. The process includes contacting a solvent with a modified cellulose to form a solution; contacting the modified cellulose solution with at least one bioactive agent to form a discontinuous phase liquid; contacting the discontinuous phase liquid with a continuous phase liquid to form an emulsion; and contacting the emulsion with a third phase liquid to extract the solvent from the emulsion, thereby forming a plurality of modified cellulose microspheres. | 12-05-2013 |
| 20130323316 | INJECTABLE MICROSPHERES FOR DERMAL AUGMENTATION AND TISSUE BULKING - The present invention relates to elastic, hydrophilic and substantially spherical microspheres useful for dermal augmentation and tissue bulking. The invention provides injectable compositions comprising the microspheres and a biocompatible carrier for use in dermal augmentation. The present invention further provides methods of dermal augmentation and tissue bulking, particularly for the treatment of skin contour deficiencies, Gastro-esophageal reflux disease, urinary incontinence, and urinary reflux disease, using the injectable compositions. | 12-05-2013 |
| 20130323317 | INJECTABLE AND SWELLABLE MICROSPHERES FOR TISSUE BULKING - The present invention relates to injectable compositions comprising biocompatible, swellable, hydrophilic, non-toxic and substantially spherical microspheres useful for tissue bulking. The invention also relates to methods of tissue bulking, particularly for the treatment of Gastro-esophageal reflux disease, urinary incontinence, or urinary reflux disease, using the injectable compositions. | 12-05-2013 |
| 20130323318 | PROTEIN FREE SURFACTANT COMPOSITION FOR PULMONARY DISEASES AND A PROCESS FOR PREPARING THE SAME - A protein free surfactant composition comprising dipalmitoylphosphatidyl choline (DPPC) and eugenol having a ratio in the range of 10:5 to 4:2 with >99% airway patency in the presence of albumin, for treating acid lung injury, adult respiratory distress syndrome and meconium aspiration syndrome. | 12-05-2013 |
| 20130330413 | NUTRITIONAL COMPOSITIONS COMPRISING CHITIN MICROPARTICLES - Nutritional oral compositions are disclosed that contain a nutritional component, such as a macronutrient or a micronutrient. The nutritional compositions also include a chitin microparticle preparation preferably obtained by microfluidisation, wherein the chitin microparticles have an average diameter of between 1 and 100 μm. | 12-12-2013 |
| 20130330414 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION - This disclosure provides therapeutic compositions and methods for inducing an anti-inflammatory response and/or treating inflammation in the gastrointestinal tract and/or accumulating gut microbial antigen-specific anti-inflammatory T cells in a patient in need thereof. | 12-12-2013 |
| 20130330415 | METHOD OF OBTAINING VIABLE SMALL TISSUE PARTICLES AND USE FOR TISSUE REPAIR - The invention provides a composition including isolated small living tissue particles, a method of making the tissue particles, and a method of using the composition to ameliorate a tissue defect. The tissue particles are composed of cells and their associated extracellular molecules and are sized, in certain embodiments, to be smaller than about 1 mm. Another aspect of the inventive tissue particles is the large percentage of viable cells. In certain embodiments, the tissue particles are made from cartilage and the composition may also contain additives such as adhesives, solutions, and bioactive agents. | 12-12-2013 |
| 20130337074 | USE OF CYTOKINE-RELEASING, BIODEGRADABLE PARTICLES IN HYALURONIC ACID FOR THE TREATMENT OF CARTILAGE DEFECTS, IN PARTICULAR OF OSTEOARTHROSIS - The present invention relates to a composition comprising, or consisting of 2-50 mg/ml hyaluronic acid, 0.1-500 mg/ml of biodegradable particles with an average mean particle diameter of 1 nm-500 μm, 1 pg/ml-10 μg/ml cytokines, where the concentrations specified are based in each case on the total volume (w/v) of the composition and where the cytokines are enclosed in the biodegradable particles, and to their use in the treatment of cartilage defects, for example traumatic cartilage defects or osteoarthrosis. | 12-19-2013 |
| 20130337075 | NANOMEDICINES FOR EARLY NERVE REPAIR - The present disclosure describes hydrophobically modified nanoparticles and polymeric nanostructures that can be utilized to for the treatment of neuronal injury or neuronal disease in an affected patient, along with methods of forming and using the nanoparticles and nanostructures. Furthermore, the nanoparticles and nanostructures are designed as “dual action” compositions to treat neuronal injury and neuronal disease via repair of damaged membrane and suppression of intracellular inflammation. | 12-19-2013 |
| 20130337076 | PARTICLES CONTAINING A GROWTH FACTOR, AND USES THEREOF - The present invention concerns particles containing at least one covalently cross-linked polysaccharide and at least one growth factor, a method of preparation, and uses thereof. | 12-19-2013 |
| 20130344157 | ENHANCEMENT OF THE EFFICACY OF THERAPEUTIC PROTEINS - A formulation for administration of at least one therapeutic mammalian protein to a mammal or a protein selected from the group, and for enhancing the absorption, distribution and release of the at least one therapeutic mammalian protein in or on the mammal, comprising at least one therapeutic mammalian protein in a micro-emulsion comprising a dispersion of vesicles or microsponges of a fatty acid based component in an aqueous or other pharmacologically acceptable carrier in which nitrous oxide is dissolved, the fatty acid based component comprising at least one long chain fatty acid based substance selected from the group consisting of free fatty acids and derivatives of free fatty acids. A method for effective delivery of at least one therapeutic mammalian protein to a mammal and for enhancing the therapeutic efficacy of such at least one therapeutic mammalian protein, comprising the step of administering the at least one therapeutic mammalian protein to the mammal in such a formulation. | 12-26-2013 |
| 20140017329 | NANOFORMULATION AND METHODS OF USE OF THYROID RECEPTOR BETA1 AGONISTS FOR LIVER TARGETING - A composition and an associated method for hepatic targeted delivery of thyroid receptor beta1 (TRβ1) agonist to a liver of a subject. The composition includes hydrophobic nanoparticles, a liver targeting moiety exterior to each nanoparticle and covalently bonded to each nanoparticle, and at least one TRβ1 agonist encapsulated within each nanoparticle. The nanoparticles include chitosan hybrid nanoparticles, amine-modified PLGA nanoparticles, solid lipid nanoparticles, and combinations thereof. The liver targeting moiety includes Glycyrrhetinic acid (GA), Lactobionic acid (LA), or combinations thereof. | 01-16-2014 |
| 20140017330 | Activated Nucleoside Analog Conjugates and Methods of Use Thereof - The present invention provides nanogel formulations and methods of use thereof. | 01-16-2014 |
| 20140017331 | POLYSACCHARIDE-CONTAINING BLOCK COPOLYMER PARTICLES AND USES THEREOF - The invention relates to new amphiphilic linear block copolymers of polysaccharides and polymers. The amphiphilic linear block copolymers do not form a true solution in water and are able to form micelles in selective solvents. Also disclosed are particles, each of which has a shell and a core, and a diameter of about 1 to 1,000 nanometers, and methods of delivering agents or removing substances, e.g., undesirable substances, from a subject or environment, by using these particles. | 01-16-2014 |
| 20140023717 | METHODS AND COMPOSITIONS FOR TREATING PROLIFERATIVE DISEASES - The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime. | 01-23-2014 |
| 20140044794 | Drug Delivery Particle and Method for Producing the Same - An object of the present invention is to develop and provide a method for conveniently introducing a nucleic acid, a peptide, and/or a low-molecular-weight compound into an empty capsid with viral early infection activities kept. The present invention provides a method for producing a drug delivery particle, comprising the steps of: mixing an empty capsid or an empty particle with a drug including a nucleic acid, a peptide, and/or a low-molecular-weight compound in a solution comprising 0.1 to 20% of a surfactant; and keeping the obtained mixed solution at −5 to 50° C. to introduce the drug into the empty capsid or the empty particle. | 02-13-2014 |
| 20140065233 | INJECTABLE MICROSPHERES FOR DERMAL AUGMENTATION AND TISSUE BULKING - The present invention relates to elastic, hydrophilic and substantially spherical microspheres useful for dermal augmentation and tissue bulking. The invention provides injectable compositions comprising the microspheres and a biocompatible carrier for use in dermal augmentation. The present invention further provides methods of dermal augmentation and tissue bulking, particularly for the treatment of skin contour deficiencies, Gastro-esophageal reflux disease, urinary incontinence, and urinary reflux disease, using the injectable compositions. | 03-06-2014 |
| 20140072646 | THYROID HORMONE ANALOGS AND METHODS OF USE - Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric form of thyroid hormone, or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed. | 03-13-2014 |
| 20140079793 | COMBINATIONS AND MODES OF ADMINISTRATION OF THERAPEUTIC AGENTS AND COMBINATION THERAPY - The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents (such as an anti-VEGF antibody), or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime. | 03-20-2014 |
| 20140079794 | GELATIN PARTICLE AND USE THEREOF, AND DEVICE FOR ADMINISTRATION OF PHYSIOLOGICALLY ACTIVE SUBSTANCE - The present invention relates to a gelatin particle, which is a thermally crosslinked non-porous spherical gelatin particle having a circularity of 0.8 or more and a dry particle diameter of 20 to 1,600 μm. The average volume swelling ratio of the gelatin particle in a case where the gelatin particle is immersed in physiological saline at 23° C. is from 200 to 2,000% relative to an average volume of the gelatin particle in a dried state. As for a swollen gelatin particle, it is preferable that the gelatin used has a jelly strength of 80 to 120 g and the swollen gelatin particle has a particle diameter of 50 to 2,000 μm. The gelatin particle can be used for blood vessel embolization and also for controlled release of physiologically active substance. | 03-20-2014 |
| 20140079795 | MUCOADHESIVE PARTICULATE FORMULATION FOR INDUCING ANTIGEN-SPECIFIC IMMUNE TOLERANCE - The present disclosure relates to a mucoadhesive composition, adapted for preventing and/or treating a pathological reaction of the immune system of an individual, by inducing a specific tolerance towards at least one antigen involved in said pathological reaction, comprising chitosan particles loaded with said at least one antigen involved in the pathological reaction, wherein the size of the loaded chitosan particles is of more than 800 nm. | 03-20-2014 |
| 20140093580 | SILK-BASED DRUG DELIVERY SYSTEM - The present invention provides for novel sustained release silk-based delivery systems. The invention further provides methods for producing such formulations. In general, a silk fibroin solution is combined with a therapeutic agent to form a silk fibroin article. The article is then treated in such a way as to alter its conformation. The change in conformation increases its crystallinity or liquid crystallinity, thus controlling the release of a therapeutic agent from the formulation. This can be accomplished as single material carriers or in a layer-by-layer fashion to load different therapeutic agents or different concentrations of these agents in each layer. | 04-03-2014 |
| 20140099380 | Microparticle Formulations for Delivery to the Lower and Central Respiratory Tract and Methods of Manufacture - Microparticle formulations of a sialidase fusion protein are produced by contacting an aqueous solution of a protein or other active agent with an organic solvent, a counterion and a scavenging agent, and chilling the solution. The microparticles are useful for preparing stable, uniform pharmaceuticals of predetermined defined dimensions. | 04-10-2014 |
| 20140099381 | METHODS AND COMPOSITIONS FOR ADMINISTRATION OF IRON - The present invention generally relates to treatment of iron-related conditions with iron carbohydrate complexes. One aspect of the invention is a method of treatment of iron-related conditions with a single unit dosage of at least about 0.6 grams of elemental iron via an iron carbohydrate complex. The method generally employs iron carbohydrate complexes with nearly neutral pH, physiological osmolarity, and stable and non-immunogenic carbohydrate components so as to rapidly administer high single unit doses of iron intravenously to patients in need thereof. | 04-10-2014 |
| 20140105995 | SILK FIBROIN SYSTEMS FOR ANTIBIOTIC DELIVERY - The present invention provides for silk fibroin-based compositions comprising one or more antibiotic agents for prevention or treatment of microbial contamination, methods of making antibiotic-containing silk scaffold, methods of stabilizing antibiotics in silk scaffolds, and methods for preventing or treating microbial contamination using the antibiotic-containing compositions. Various methods may be used to embed the antibiotic(s) into the silk fibroin-based compositions. The antibiotic-containing compositions of the invention are particular useful for stabilizing antibiotics, preventing bacterial infections, and for medical implants, tissue engineering, drug delivery systems, or other pharmaceutical or medical applications. | 04-17-2014 |
| 20140120169 | DEVICE AND METHOD FOR ENCAPSULATION OF HYDROPHILIC MATERIALS - A process for preparing polymeric composite particles includes the steps of preparing an oil phase containing a biodegradable polymer and a water phase containing a hydrophilic compound or nanoparticle and emulsifying the oil phase in the water phase to form emulsions. Then solvent is removed from the emulsions to prepare the particles in the form of capsules and spheres in sizes from 0.01 μm (10 nm) to 50 μm. | 05-01-2014 |
| 20140127310 | TREATMENT OF DISEASE WITH POLY-N-ACETYLGLUCOSAMINE NANOFIBERS - This application relates to compositions comprising shortened fibers of poly-N-acetylglucosamine and/or a derivative thereof (“sNAG nanofibers”) and the use of such compositions in the treatment of disease. | 05-08-2014 |
| 20140134260 | CATIONIC LIPIDS AND METHODS FOR THE DELIVERY OF THERAPEUTIC AGENTS - The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid in vivo. The compositions of the present invention are highly potent, thereby allowing effective know-down of a specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art. | 05-15-2014 |
| 20140141093 | POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS AND ANTAGONISTS - The invention relates to anti-TNFR1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD. | 05-22-2014 |
| 20140141094 | SOLID COMPOSITIONS FOR PHARMACEUTICAL USE - The invention relates to solid compositions that may be suitable for administering a therapeutic agent to a subject. The invention also relates to methods of making such solid compositions. The invention further relates to methods of treating a disease, condition, or disorder by administering to a subject such solid compositions. | 05-22-2014 |
| 20140154329 | Process For Stabilizing An Adjuvant Containing Vaccine Composition - The present invention relates to a process for stabilizing an adjuvant containing vaccine composition, an adjuvanted vaccine composition in dry form and in particular a process for stabilizing an influenza vaccine composition, particularly an adjuvanted influenza vaccine composition in dry form. | 06-05-2014 |
| 20140154330 | SPHERICAL PARTICLES OF CLOPIDOGREL BISULFATE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND PREPARATION METHOD THEREOF - Disclosed are spherical particles of clopidogrel bisulfate and a pharmaceutical composition containing the same. The spherical particles can be used for preparing a tablet having sufficient hardness through direct compression, by improving unformulable properties of clopidogrel bisulfate such as compressibility, flowability and strong surface electrostatic charges, reduce a problem in compressing tablets such as weight variation, sticking, etc., and the risk of form conversion, and improve physiochemical stability. Therefore, the spherical particles of the present invention may be used as therapeutics for arteriosclerosis, stroke, myocardial infarction and atherosclerosis. | 06-05-2014 |
| 20140161895 | PHARMACEUTICAL COMPOSITIONS OF DEXTRAN POLYMER DERIVATIVES - Pharmaceutical compositions are provided comprising an active agent and a dextran polymer derivative. The compositions include from 0.01 to 99 wt % of an active agent and from 1 to 99.99 wt % of a dextran polymer derivative. The dextran polymer derivative is selected from dextran acetate, dextran propionate, dextran succinate, dextran acetate propionate, dextran acetate succinate, dextran propionate succinate, dextran acetate propionate succinate, and mixtures thereof. | 06-12-2014 |
| 20140161896 | PARTICLES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES - A composition of matter comprising non-cellular particles, which comprise a lysosomal enzyme and/or a small molecule which increases an amount and/or activity of a lysosomal enzyme. | 06-12-2014 |
| 20140170228 | COMBINATION THERAPY METHODS FOR TREATING PROLIFERATIVE DISEASES - The present invention provides combination therapy methods of treating a proliferative disease (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include the administration of an effective amount of at least one other agent that modifies the epigenetics in a cell. | 06-19-2014 |
| 20140178486 | CANCER TREATEMENTS - This document provides methods and materials related to treating cancer (e.g., skin cancer). For example, methods and materials relating to the use of a composition containing albumin-containing nanoparticle/antibody complexes (e.g., Abraxane®/anti-VEGF polypeptide antibody complexes) to treat cancer (e.g., skin cancer) are provided. | 06-26-2014 |
| 20140193505 | BIODEGRADABLE CARRIER WITH ADJUSTABLE ZETA POTENTIALS AND PARTICLE SIZES, METHOD FOR MAKING THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - The present invention is related to a biodegradable carrier with adjustable zeta potentials and particle sizes, a method for making the same, and a pharmaceutical composition comprising the same. In such a method, a first solution comprising a first biodegradable macromolecule is prepared, and a second solution comprising a second biodegradable macromolecule is also prepared according to a desired zeta potential of a biodegradable carrier and further added into the first solution to form a mixture solution. The biodegradable carrier with the desired zeta potentials is formed by the attraction force between the different electric properties. Then, the mole number of the first biodegradable macromolecule and the second biodegradable macromolecule in the mixture solution are proportionally adjusted according to a desired particle size of the biodegradable carrier. Therefore, the zeta potential and the particle size of the biodegradable carrier are adjustable artificially. | 07-10-2014 |
| 20140193506 | PROTECTION AGAINST INFLUENZA INFECTION BY GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR - Alveolar macrophages contribute to host defenses against influenza. Enhancing their function contributed to protection against influenza and other acute lethal pulmonary infections. Wild-type mice and Tg mice expressing GM-CSF in the lung were infected with influenza virus, and lung pathology, weight loss and mortality were measured. GM-CSF was also administered to lungs of wild-type mice that were infected with influenza virus. All Tg mice expressing GM-CSF in the lungs survived with greatly reduced weight loss and lung injury and histologic evidence of a rapid host inflammatory response that controlled infection vs. wild-type mice not expressing GM-CSF in the lungs. This resistance to influenza was abrogated by elimination of alveolar phagocytes, but not by depletion of T cells, B cells or neutrophils. Tg mice had far more alveolar macrophages than wild-type mice and were more resistant to influenza-induced apoptosis. Delivery of intranasal GM-CSF to wild-type mice also conferred influenza resistance. Therefore, GM-CSF confers resistance to influenza by enhancing innate immune mechanisms that depend on alveolar macrophages. Pulmonary delivery of GM-CSF is therefore useful for reducing the significant morbidity and mortality due to influenza virus and is similarly useful in pulmonary infection caused by other infectious viral and bacterial agents. | 07-10-2014 |
| 20140193507 | PREPARATION OF INJECTABLE SUSPENSIONS HAVING IMPROVED INJECTABILITY - Injectable compositions having improved injectability. The injectable compositions include microparticles suspended in an aqueous injection vehicle having a viscosity of at least 20 cp at 20° C. The increased viscosity of the injection vehicle that constitutes the fluid phase of the suspension significantly reduces in vivo injectability failures. The injectable compositions can be made by mixing dry microparticles with an aqueous injection vehicle to form a suspension, and then mixing the suspension with a viscosity enhancing agent to increase the viscosity of the fluid phase of the suspension to the desired level for improved injectability. | 07-10-2014 |
| 20140193508 | SURFACE BINDING OF NANOPARTICLE BASED DRUG DELIVERY TO TISSUE - Microparticles and nanoparticles and compositions thereof are provided. The microparticles and nanoparticles and compositions may be used for the treatment of musculoskeletal disease, such as osteoarthritis and injury. | 07-10-2014 |
| 20140193509 | CARRIER PELLETS, METHOD FOR PRODUCTION THEREOF AND USE THEREOF - The invention relates to a method for the production of carrier pellets for pharmaceutical active substances. Likewise, the invention relates to such carrier pellets and also to pharmaceutical formulations containing these. The carrier pellets according to the invention are used for transporting and releasing pharmaceutical active substances, in particular in the human body. | 07-10-2014 |
| 20140212503 | DELIVERY SYSTEM - The present invention provides three-dimensional, nanoscale delivery systems, particularly well adapted for delivery of nucleic acids and/or nucleic acid associated entities. | 07-31-2014 |
| 20140220149 | METHOD FOR PREVENTION AND TREATMENT OF REFLUX INJURY IN THE AERODIGESTIVE TRACT AND LARYNGOPHARYNX CAUSED BY PEPSIN - A method for treating or preventing disorders, diseases, and symptom of reflux, that is laryngopharyngeal reflux (LPR), in the laryngopharynx caused by pepsin comprises orally administering to the laryngopharynx of a patient an effective amount of cellulose powder. A method for treating or preventing damage to the lining membranes of at least some of the aerodigestive tract, the damage caused by pepsin, comprises coating at least some of the lining membranes with an effective amount of a cellulose powder. Upon inhalation of the powder, the powder coats the lining membranes. Upon coating the lining membranes, the powder becomes a gel. The gel prevents the pepsin from binding with the lining membranes, thereby preventing damage caused by pepsin in laryngopharyngeal reflux or in extra-esophageal reflux. | 08-07-2014 |
| 20140242180 | NANOPARTICLES FOR CONTROLLING BLEEDING AND DRUG DELIVERY - A temperature stable nanoparticle is provided comprising a core, a water soluble polymer and a peptide, the water soluble polymer attached to the core at a first terminus of the water soluble polymer, the peptide attached to a second terminus of the water soluble polymer, the peptide comprising an RGD amino acid sequence, the water soluble polymer of having sufficient length to allow binding of the peptide to glycoprotein lib/Ilia (GPIIb/llla). In one aspect, the nanoparticle has a melting temperature over 35° C. In various aspects, the nanoparticle has a spheroid shape and a diameter of less than 1 micron. | 08-28-2014 |
| 20140248367 | SPRAY-DRIED PHARMACEUTICAL COMPOSITIONS COMPRISING ACTIVE AGENT NANOPARTICLES - Provided herein are dry pharmaceutical compositions for transmucosal delivery, comprising spray-dried particles that include pharmaceutically active agent nanoparticles, a binder, and a pharmaceutically acceptable carrier, where the active agent nanoparticles have an average particle size diameter prior to spray-drying of less than about 1 μm, and wherein up to 10% of the spray-dried particles have a particle size of less than 10 μm; at least 50% of the spray-dried particles have a particle size of at least about 15 μm; and at least 90% of the spray-dried particles have a particle size of up to about 55 μm. Also provided are methods for making such pharmaceutical compositions and therapeutic methods comprising transmucosally administering the compositions, such as intranasally or intravaginally. | 09-04-2014 |
| 20140255504 | ENHANCEMENT OF THE EFFICACY OF THERAPEUTIC PROTEINS - A formulation for administration of at least one therapeutic mammalian protein to a mammal or a protein selected from the group, and for enhancing the absorption, distribution and release of the at least one therapeutic mammalian protein in or on the mammal, comprising at least one therapeutic mammalian protein in a micro-emulsion comprising a dispersion of vesicles or microsponges of a fatty acid based component in an aqueous or other pharmacologically acceptable carrier in which nitrous oxide is dissolved, the fatty acid based component comprising at least one long chain fatty acid based substance selected from the group consisting of free fatty acids and derivatives of free fatty acids. A method for effective delivery of at least one therapeutic mammalian protein to a mammal and for enhancing the therapeutic efficacy of such at least one therapeutic mammalian protein, comprising the step of administering the at least one therapeutic mammalian protein to the mammal in such a formulation. | 09-11-2014 |
| 20140271900 | High Cleaning Silica with Low Abrasion and Method for Making Same - Silica materials having high cleaning and low abrasion properties are described, together with methods of making such materials and dentifrice compositions comprising the silica materials. | 09-18-2014 |
| 20140271901 | Management of Tractional Membranes - Methods and compositions are provided here to manage tractional membranes, as well as other diseases and disorders of the eye. Compositions comprising microbubbles associated with enzymes or vitreolytic agents, are provided. The method of the present invention involves administration of the microbubble and an enzyme or vitreolytic agent to a subject in need thereof, followed by application of ultrasound. | 09-18-2014 |
| 20140271902 | PARTICULATE HYALURONIC ACID FORMULATIONS FOR CELLULAR DELIVERY OF BIOACTIVE AGENTS - There is presently provided a suspension of immiscible particles in a solution, wherein the particles comprise an agglomeration of a bioactive agent; and a plurality of conjugates of a hyaluronic acid and a flavonoid wherein the particles are on average from about 15 nm to about 300 nm in diameter and wherein the bioactive agent is releasably retained in the particles by the flavonoid. There is also provided a therapeutic formulation comprising such a suspension and methods for using the suspension and therapeutic formulation, including for delivery of a bioactive agent to a cell and for treating a disease, including cancer. | 09-18-2014 |
| 20140294985 | BONE PASTES COMPRISING BIOFUNCTIONALIZED CALCIUM PHOSPHATE CEMENTS WITH ENHANCED CELL FUNCTIONS FOR BONE REPAIR - The invention provides injectable, biofunctional agent-containing calcium phosphate cement bone pastes for bone tissue engineering, and methods of making and using the same. | 10-02-2014 |
| 20140302157 | NANOPARTICLE FORMULATIONS AND USES THEROF - The present invention provides compositions comprising nanoparticles comprising: 1) a drug, such as a hydrophobic drug derivative; and 2) a carrier protein. Also provided are methods of treating diseases (such as cancer) using the compositions, as well as kits and unit dosages. | 10-09-2014 |
| 20140302158 | INFLUENZA VIRUS-LIKE PARTICLES (VLPS) COMPRISING HEMAGGLUTININ PRODUCED NICOTIANA TABACUM - The present invention relates to a composition or composition of bilayer lipid vesicles displaying an influenza virus antigen and carbohydrate, and the production thereof in | 10-09-2014 |
| 20140308361 | COMPOSITION FOR MANAGEMENT OF PERIODONTAL DISEASES - The composition for management of periodontal diseases includes a gel matrix having a polymer system and a plurality of microspheres dispersed in the polymer system. The polymer system contains about one-half a dose of medicament, while the micro spheres contain the remainder. Upon administration of the composition into the periodontal cavity, the medicament in the polymer system provides an initial therapeutic benefit, while the remainder of the medication is released over time via degradation of the microspheres. This biphasic pattern of medicament delivery provides increased efficacy of the medicament through sustained delivery of the same. | 10-16-2014 |
| 20140308362 | INJECTABLE SILK FIBROIN PARTICLES AND USES THEREOF - The inventions provided herein relate to compositions, methods, delivery devices and kits for repairing or augmenting a tissue in a subject. The compositions described herein are injectable such that they can be placed in a tissue to be treated with a minimally-invasive procedure (e.g., by injection) and/or be molded flexibly into a tissue void of any shape and/or size. In some embodiments, the composition described herein comprises a plurality of silk fibroin particles, which can retain their original volume within the tissue for a period of time. The compositions can be used as a filler to replace a tissue void, e.g., for tissue repair and/or augmentation, or as a scaffold to support tissue regeneration and/or reconstruction. In some embodiments, the compositions described herein can be used for soft tissue repair or augmentation. | 10-16-2014 |
| 20140322344 | VACCINE PREPARATION FOR CANCER TREATMENT - A vaccine preparation for treating cancer includes a complex of a hydrophobized polysaccharide and at least one synthetic long peptide derived from a tumor-specific antigenic protein and/or a pathogen-derived antigenic protein. The at least one synthetic long peptide contains at least one CD8+ cytotoxic T-cell recognition epitope and at least one CD4+ helper T-cell recognition epitope. The complex is simultaneously administered to the patient with at least one immunopotentiating agent. | 10-30-2014 |
| 20140322345 | NOVEL SLOW-RELEASING OPHTHALMIC COMPOSITIONS COMPRISING POVIDONE IODINE - The present invention provides novel slow-releasing ophthalmic compositions containing Povidone Iodine (PVP-I) and uses thereof in the treatment of acute infections of at least one eye tissue from bacterial, mycobacterial, viral, fungal, or amoebic causes and for preventing such infections in appropriate clinical settings. Each of the ophthalmic compositions contains povidone iodine, osmotic pressure regulator, suspending agent and EDTA-Na, wherein povidone iodine exists as microsphere particles formed by PVP-I and sodium alginate. | 10-30-2014 |
| 20140328935 | Genes Encoding Major Capsid Protein L1 of Human Papilloma Virus - The present invention discloses a codon-optimized gene encoding major capsid protein L1 of human papilloma virus, which is capable, after transduced into a yeast cell, of efficiently expressing the major capsid protein L1 of human papilloma virus. The present invention also discloses an immunogenic macromolecule which is essentially produced by expression of said codon-optimized gene encoding the major capsid protein L1 of human papilloma virus in a yeast cell. The present invention further discloses the use of said immunogenic macromolecule and a composition comprising said immunogenic macromolecule. | 11-06-2014 |
| 20140328936 | NOVEL PHARMACEUTICAL STATIN COMPOSITION - The invention relates to a pharmaceutical composition, comprising or consisting of: 10 to 30 weight percent of at least a pharmaceutically active amount of a pharmaceutical substance selected from the group comprising statins, in particular water-insoluble, oxidatively degradable statins, preferably cerivastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, or combinations thereof, 30 to 70 weight percent of lactose hydrate, 2 to 15 weight percent of microcrystalline cellulose, 5 to 25 weight percent of a partially water-soluble starch, 0.2 to 4 weight percent of at least one alkali and/or alkaline-earth salt of stearic acid and/or stearyl fumaric acid, wherein the composition contains no antioxidatively active substances such as chain terminators, reductants, free-radical scavengers, and complexing agents. The invention further relates to a method for the production thereof, to a composition that can be obtained in the method, and to the use of the pharmaceutical composition according to the invention. | 11-06-2014 |
| 20140335192 | DELIVERY OF RNA INTERFERING AGENTS - Provided are compositions for the delivery of biomolecules, such as nucleic acids into target cells, and methods of making and using same. The compositions comprise nucleic acid delivery complexes that include a nucleic acid, such as an RNA interfering agent, an RNA neutralization domain, a double stranded RNA binding domain, and a protein transduction domain. | 11-13-2014 |
| 20140342006 | Methods for Preparing Injectable Protein Microparticle Suspensions - A method for preparing a microparticle suspension, which comprises: (a) providing protein microparticles having a median diameter between 5 and 13 microns and a GSD less than 2.5; (b) combining the microparticles with a liquid, pharmaceutically acceptable, water miscible media to create a first mixture; (c) adding an aqueous media to the first mixture to create second mixture; and (d) mixing the second mixture to create a microparticle suspension is described. The suspension are injectable even when they contain a relatively high concentration of protein. | 11-20-2014 |
| 20140342007 | METHODS OF MANUFACTURING BIOACTIVE GELS FROM EXTRACELLULAR MATRIX MATERIAL - The present invention is directed to methods of manufacturing bioactive gels from ECM material, i.e., gels which retain bioactivity, and can serve as scaffolds for preclinical and clinical tissue engineering and regenerative medicine approaches to tissue reconstruction. The manufacturing methods take advantage of a new recognition that bioactive gels from ECM material can be created by digesting particularized ECM material in an alkaline environment and neutralizing to provide bioactive gels. | 11-20-2014 |
| 20140348935 | TREATMENT OF FOOD INTOLERANCE AND FOOD ALLERGY WITH IgA - A process is provided for inhibiting symptoms of food allergy or food intolerance in a subject that includes the oral adminstration to the subject suffering from food allergy or food intolerance an IgM. When administered in a therapeutic quantity based on the subject characteristics and the type of IgM, symptoms of food allergy or food intolerance in that subject are inhibited. Even non-secretory forms of IgM are effective when administered orally. | 11-27-2014 |
| 20140356442 | PHARMACEUTICAL COMPOSITIONS OF TRIPTORELIN MICROSPHERES - Sustained release triptorelin microspheres include triptorelin or a salt of triptorelin, a copolymer of lactide and glycolide, and glucose or mannitol. The sustained release triptorelin microspheres have a relatively high initial release after administration, which allows the drug to produce its pharmaceutical effects immediately and to maintain long-term steady pharmaceutical effects. | 12-04-2014 |
| 20140356443 | PHARMACEUTICAL COMPOSITION COMPRISING STABLE, AMORPHOUS, HYBRID NANOPARTICLES OF AT LEAST ONE PROTEIN KINASE INHIBITOR AND AT LEAST ONE POLYMERIC STABILIZING AND MATRIX-FORMING COMPONENT - The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy. | 12-04-2014 |
| 20140377366 | BIODEGRADABLE POLYMERS FOR DELIVERY OF THERAPEUTIC AGENTS - Methods, processes, systems, and compositions for treating disease are disclosed. In some cases, the present disclosure provides for delivery of therapeutic agents, in an active form, to a localized area, over an extended period of time. In one embodiment, the disclosed composition may comprise a therapeutic agent and a biodegradable polymer and/or a biodegradable polymer microsphere. | 12-25-2014 |
| 20140377367 | HPV Chimaeric Particle - This invention relates to a chimaeric human papillomavirus (HPV) virus like particle (VLP) having a diameter of about 30 nm. The invention further relates to methods of treatment and/or prophylaxis of HPV infection and/or cervical cancer by administration of the chimaeric HPV VLP of the invention to a subject. | 12-25-2014 |
| 20140377368 | CHITOSAN BEADS AND FILLER COMPRISING SUCH BEADS - The present invention pertains to chitosan beads consisting of chitosan cross-linked with citrate ions. The present invention furthermore pertains to a filler comprising such chitosan-citrate beads. In one embodiment of the instant invention the filler is a dermal filler. In one further embodiment of the present invention the dermal filler is for the treatment of wrinkles and/or folds. In another embodiment of the instant invention the filler is for use in the treatment of a medical condition. The filler provided in the present invention may further comprise one or more active pharmaceutical ingredients. Further, the present invention pertains to a process for preparing the filler as claimed herein. | 12-25-2014 |
| 20150010642 | COMPOSITION OF A BONE REPAIR MIXTURE - A composition of a bone repair mixture has a quantity of allograft particulate bone having a bone particle distribution of particle sizes less than 700 micron and a quantity of biologic carrier material intermixed with the particulate bone. The biologic carrier material is one of collagen, porous collagen or a collagen mixture. Preferably, the carrier material is exclusively collagen. | 01-08-2015 |
| 20150030685 | Sugar-Free Oral Transmucosal Fentanyl Citrate Lozenge Dosage Forms - A sugar-free, pharmaceutical composition comprising an oral transmucosal solid dosage form which includes an adherent carrier preblend mixture of a highly potent pharmaceutical agent, and dextrates, hydrated the composition further including a pharmaceutically acceptable sugar-free excipient. | 01-29-2015 |
| 20150037426 | MODIFIED STARCH MATERIAL OF BIOCOMPATIBLE HEMOSTASIS - A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal. | 02-05-2015 |
| 20150037427 | NANO DELIVERY SYSTEMS - The present invention makes use of a unique methodology of double nano-encapsulation for protecting and controlling the release of active agents, either hydrophobic or hydrophilic, from stable nanoparticles of opposite characteristics. The protection of the active agent was achieved by loading the agent to be protected, into nanocarriers, which were subsequently encapsulated into sub-micron nanoparticles. The sub-micron nanoparticles formation has been successfully achieved by the use of novel nano spray techniques. | 02-05-2015 |
| 20150050355 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS AND METHODS OF PREPARATION THEREOF - A particulate SAE-CD composition is provided. The SAE-CD composition has an advantageous combination of physical properties not found in known solid forms of SAECD. In particular, the SAE-CD composition possesses an advantageous physicochemical and morphological property profile such that it can be tailored to particular uses. The SAE-CD composition of the invention has improved flow and dissolution performance as compared to known compositions of SAE-CD. | 02-19-2015 |
| 20150050356 | NANOPARTICLE COMPRISING RAPAMYCIN AND ALBUMIN AS ANTICANCER AGENT - The present invention features methods for treating, stabilizing, preventing, and/or delaying cancer by administering nanoparticles that comprise rapamycin or a derivative thereof. The invention also provides compositions (e.g., unit dosage forms) comprising nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof. The invention further provides combination therapy methods of treating cancer comprising administering to an individual an effective amount of nanoparticles that comprise rapamycin or a derivative thereof and a second therapy. | 02-19-2015 |
| 20150056293 | SILK NANOSPHERES AND MICROSPHERES AND METHODS OF MAKING SAME - The present invention provides for methods of preparing silk nanoparticles and microparticles, methods of encapsulating an active agent into the silk nano- and microparticles and compositions comprising these silk particles. In particular, the silk spheres are prepared from phase separation of silk and polyvinyl alcohol (PVA), without exposure to an organic solvent. The method employs a chemical, PVA, which is an FDA-approved ingredient in drug formulations. Different parameters can be adjusted to control the size and shape of the silk spheres during the fabrication process. The silk particle compositions of the present invention may also encapsulate active agents or chemicals. Such compositions allow the active agents to be controllably and sustainably released to the target organs or tissues. The silk composition entrapping active agents also provides for a long-term storage medium for the active agents so entrapped. The silk nano- and microparticles of the present invention are thus suitable for a variety of biomedical and pharmaceutical applications, such as drug delivery or tissue engineering. | 02-26-2015 |
| 20150056294 | METHODS AND COMPOSITIONS FOR PREPARING A SILK MICROSPHERE - Provided herein relates to methods and compositions for preparing a silk microsphere and the resulting silk microsphere. In some embodiments, the methods and compositions described herein are all aqueous, which can be used for encapsulating an active agent in a silk microsphere, while maintaining activity of the active agent during processing. In some embodiments, the resulting silk microsphere can be used for sustained delivery of an active agent encapsulated therein. | 02-26-2015 |
| 20150064267 | NANOPARTICLES FOR CONTROLLED LYSIS OF BLOOD CLOTS - Fibrinolytic nanoparticles including a polymeric core having a surface that is functionalized with a cationic amphiphilic compound, and a fibrinolytic agent dispersed within the core, are described herein. The fibrinolytic nanoparticles can be used in method of dissolving a blood clot in a subject by administering to the subject a therapeutically effective amount of fibrinolytic nanoparticles. | 03-05-2015 |
| 20150072017 | CARRIER MATERIALS FOR PROTEIN DELIVERY - Osteogenic implants, carriers and concentrates are described, along with methods of making and using the same. The implants include a carrier and, optionally, an osteoinductive agent. The carrier includes a mineral component, a binder and, optionally, a collagen additive, while the osteoinductive agent may be a protein such as a bone morphogenetic protein. | 03-12-2015 |
| 20150079189 | Nanoparticulate Compositions for Targeted Delivery of Acid Labile, Lipophilic Prodrugs of Cancer Chemotherapeutics and Their Preparation - In one embodiment, the present application discloses synthetic LDL nanoparticles comprising mixtures of components selected from the group consisting of phospholipids, triglycerides, cholesterol ester and free cholesterol; optionally further comprising an agent selected from the group consisting of natural antioxidants, ubiquinol and vitamin E, and methods for preparing the synthetic nanoparticles. The disclosed synthetic LDL nanoparticles are capable of selectively delivering lipophilic drugs and prodrugs to cellular targets expressing LDL receptors after intra venous injection. | 03-19-2015 |
| 20150086642 | MODIFIED PECTINS, COMPOSITIONS AND METHODS RELATED THERETO - The present invention provides compositions of modified pectin and methods for preparing and using them. | 03-26-2015 |
| 20150099004 | APREPITANT ORAL LIQUID FORMULATIONS - A liquid pharmaceutical compositions comprising Aprepitant is preferably prepared as an oral suspension dosage form for the prevention and control of acute and delayed chemotherapy induced nausea and vomiting, and/or for prevention of postoperative nausea and vomiting. | 04-09-2015 |
| 20150099005 | HIGH DRUG LOADING SYSTEM TO CO-DELIVER ANTICANCER DRUGS AND NUCLEIC ACIDS FOR CANCER THERAPY - A high drug loading system is described comprising of at least one anticancer drug; at least one peptide; and at least one nucleic acid. | 04-09-2015 |
| 20150110885 | PARENTERAL PHARMACEUTICAL COMPOSITION CONTAINING COSYNTROPIN - The present invention describes novel and improved parenteral depot pharmaceutical compositions containing cosyntropin (tetracosactide), for the treatment of infantile spasm. | 04-23-2015 |
| 20150118319 | PROTEOLYSIS-RESISTANT CAPSID OF CHIMERIC HEPATITIS E VIRUS AS AN ORAL DELIVERY VECTOR - This invention provides a peptide/nucleic acid composition for oral/mucosal, dual-modal activation of immune protection systems. | 04-30-2015 |
| 20150125541 | GEL-LIKE MASS COMPRISING NATURAL OR SYNTHETIC POLYMERS AND METHOD FOR PRODUCING THE GEL-LIKE MASS - In a gel-like mass having natural or synthetic polymers, preferably polygalactomannans, at least one cross-linking agent and further ingredients, according to this invention that the at least one cross-linking agent is of amphiphilic core-shell nanoparticles. This invention further refers to a method for producing a gel-like mass, a composition for producing a gel-like mass comprising natural or synthetic polymers, preferably polygalactomannans and amphiphilic core-shell nanoparticles and the use of a gel-like mass as drug delivery system for topical medication. | 05-07-2015 |
| 20150132398 | VACCINE FORMULATION OF MANNOSE COATED PEPTIDE PARTICLES - A vaccine formulation as disclosed which is comprised of a pharmaceutically acceptable carrier in a plurality of particles with mannose on their surface. The particles are comprised of a biocompatible polymer which maybe a co-polymer such as PLGA combined with a peptide of a sequence which corresponds to a sequence on a surface of a pathogen. A plurality of different groups of particles are provided in the formulation wherein the particles within any single group include peptides of identical amino acid sequence. The particles are sized such that they are sufficiently large so as to prevent more than a single particle from being presented to a single immune system cell. | 05-14-2015 |
| 20150140108 | LIPIDATED GLYCOSAMINOGLYCAN PARTICLES FOR THE DELIVERY OF NUCLEIC ACIDS - There are provided compositions comprising lipidated glycosaminoglycan particles, methods for their preparation and uses thereof for the efficient in-vivo and in-vitro delivery of nucleic acids, such as, siRNA molecules. | 05-21-2015 |
| 20150140109 | DOCETAXEL-BASED PROLONGED-RELEASE CANCER TREATMENT DRUG - The present invention relates to the field of pharmacology and medicine, specifically to a new generation of anticancer drugs with the cytostatic action based on docetaxel. In the drug composition of the invention docetaxel is included in biodigestible stable nanoparticles. The nanoparticles comprise of docetaxel, PLGA, serum albumin and D-mannitol The developed drug is proposed to be manufactured as enterosoluble tablets, capsules granules, powder, or in any other peroral form. | 05-21-2015 |
| 20150140110 | COMPOSITIONS OF JASMONATE COMPOUNDS AND METHODS OF USE - The disclosure describes nanocarried and/or microcarried jasmonate compounds and their pharmaceutical compositions, as well as use thereof for treating or preventing angiogenesis-related or NF-κB-related disorders. Also disclosed are methods of making the nanocarried and/or microcarried compounds and their compositions. | 05-21-2015 |
| 20150147404 | LEDGF PEPTIDES AND FORMULATIONS THEREOF FOR TREATMENT OF DEGENERATIVE DISORDERS - LEDGF peptides with anti-protein aggregation activity and methods of use are provided. The LEDGF peptides disclosed herein demonstrate an ability to treat degenerative diseases and diseases with various cellular stresses including oxidative stress and protein-aggregation stress. In addition, extended release formulations, including formulations suitable for ophthalmic administration are provided. | 05-28-2015 |
| 20150290287 | THERAPEUTIC APPLICATIONS OF SMAD7 - The invention provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of Smad7 compositions delivered locally or systematically to a site of inflammation and/or tissue damage is described. Other specific embodiments concern treatment or prevention of side effects caused by radiation and/or chemotherapy, including but not limited to mucositis. | 10-15-2015 |
| 20150313866 | BREAST CANCER THERAPY BASED ON HORMONE RECEPTOR STATUS WITH NANOPARTICLES COMPRISING TAXANE - The present invention relates to methods and kits for the treatment of breast cancer based on hormone receptor status of progesterone receptor and estrogen receptor comprising the administration of a taxane alone, in combination with at least one other and other therapeutic agents, as well as other treatment modalities useful in the treatment of breast cancer. In particular, the invention relates to the use of nanoparticles comprising paclitaxel and albumin (such as Abraxane®) either alone or in combination with other chemotherapeutic agents or radiation, which may be used for the treatment of breast cancer which does not express estrogen receptor and/or progesterone receptor. | 11-05-2015 |
| 20150320694 | MUCOADHESIVE NANOPARTICLE DELIVERY SYSTEM - The present disclosure relates generally to a mucoadhesive nanoparticle delivery system. The nanoparticles are formed from amphiphilic macromolecules conjugated to a mucosal targeting moiety in such a manner that the surface of the nanoparticle is coated with the targeting moiety. The surface density of the targeting moiety can be tuned for adjustable targeting of the nanoparticles to a mucosal site without substantially compromising the stability of the particles. The particles were found to have high loading efficiency and sustained release properties at the mucosal site. The present disclosure also relates to polymers and macromolecules useful in the preparation of the mucoadhesive nanoparticles, as well as compositions, methods, commercial packages, kits and uses related thereto. | 11-12-2015 |
| 20150320901 | Hemostatic Foam - The invention is directed a hemostatic foam, to a process for preparing a biodegradable hemostatic foam, and to the use of said foam. The hemostatic foam comprises a blend of a chitosan hemostatic agent and a polymer, which polymer provides the foam with a porosity of 85-99% and a foam density of 0.01-0.2 g/cm | 11-12-2015 |
| 20150328160 | REHYDRATABLE PHARMACEUTICAL PRODUCT - A pharmaceutical product comprising lyophilised polymer matrix including a biologically active compound, of particular utility for embolisation, having improved rehydration properties is packaged in an airtight package under vacuum. | 11-19-2015 |
| 20150328287 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR FABRICATION OF SOLID MASSES COMPRISING GLUCOSE REGULATING PROTEINS - Embodiments of the invention provide shaped masses comprising one or more drugs such as proteins or polypeptides and methods for forming such shaped masses. One embodiment provides a shaped mass comprising a drug such as a protein or polypeptide having a biological activity in the body of a mammal. The shaped mass is formed by compression of a precursor material comprising the drug wherein an amount of biologically active drug in the mass is a preserved above a minimum level. Drugs which may be incorporated into the shaped mass may include one or more glucose regulating proteins such as insulin, incretins; and immunoglobulins such as TNF-inhibiting antibodies or interleukin neutralizing antibodies. Embodiments of the shaped mass may be incorporated into a tissue penetrating member which is inserted into the intestinal wall allowing for the oral delivery of proteins and peptides which would otherwise be degraded in the intestinal tract. | 11-19-2015 |
| 20150329631 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR FABRICATION OF SOLID MASSES COMPRISING TNF-INHIBITING ANTIBODIES - Embodiments of the invention provide shaped masses comprising one or more drugs such as proteins or polypeptides and methods for forming such shaped masses. One embodiment provides a shaped mass comprising a drug such as a protein or polypeptide having a biological activity in the body of a mammal. The shaped mass is formed by compression of a precursor material comprising the drug wherein an amount of biologically active drug in the mass is a preserved above a minimum level. Drugs which may be incorporated into the shaped mass may include one or more glucose regulating proteins such as insulin, incretins; and immunoglobulins such as TNF-inhibiting antibodies or interleukin neutralizing antibodies. Embodiments of the shaped mass may be incorporated into a tissue penetrating member which is inserted into the intestinal wall allowing for the oral delivery of proteins and peptides which would otherwise be degraded in the intestinal tract. | 11-19-2015 |
| 20150329633 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR FABRICATION OF SOLID MASSES COMPRISING ANTI-INTERLEUKIN ANTIBODIES - Embodiments of the invention provide shaped masses comprising one or more drugs such as proteins or polypeptides and methods for forming such shaped masses. One embodiment provides a shaped mass comprising a drug such as a protein or polypeptide having a biological activity in the body of a mammal. The shaped mass is formed by compression of a precursor material comprising the drug wherein an amount of biologically active drug in the mass is a preserved above a minimum level. Drugs which may be incorporated into the shaped mass may include one or more glucose regulating proteins such as insulin, incretins; and immunoglobulins such as TNF-inhibiting antibodies or interleukin neutralizing antibodies. Embodiments of the shaped mass may be incorporated into a tissue penetrating member which is inserted into the intestinal wall allowing for the oral delivery of proteins and peptides which would otherwise be degraded in the intestinal tract. | 11-19-2015 |
| 20150335786 | METHODS OF MANUFACTURING BIOACTIVE GELS FROM EXTRACELLULAR MATRIX MATERIAL - The present invention is directed to methods of manufacturing bioactive gels from ECM material, i.e., gels which retain bioactivity, and can serve as scaffolds for preclinical and clinical tissue engineering and regenerative medicine approaches to tissue reconstruction. The manufacturing methods take advantage of a new recognition that bioactive gels from ECM material can be created by digesting particularized ECM material in an alkaline environment and neutralizing to provide bioactive gels. | 11-26-2015 |
| 20150352176 | OIL-FREE AND FAT-FREE AQUEOUS SUSPENSIONS OF CYCLOSPORIN - Compositions that are oil-free and fat-free aqueous suspensions of cyclosporin and contain a cyclosporin (e.g., cyclosporine), a hydrophilic pharmaceutically acceptable solvent in which the cyclosporin (e.g., cyclosporine) is soluble, a dispersing agent, a suspending agent and an aqueous vehicle are disclosed. Methods of producing such compositions, as well as methods of using the compositions to treat ophthalmic disorders are also disclosed. | 12-10-2015 |
| 20150359905 | COMPOSITION OF ANTI-ENDO180 ANTIBODIES AND METHODS OF USE FOR THE TREATMENT OF CANCER AND FIBROTIC DISEASES - The present invention provides antibodies or antigen-binding fragments thereof that specifically bind the ENDO | 12-17-2015 |
| 20150368616 | METHODS FOR INDUCTION OF CELL FATES FROM PLURIPOTENT CELLS - A method of inducing pancreatic fates from human multipotent or pluripotent cells includes obtaining a cell population comprising human multipotent or pluripotent cells and providing the cell population with at least three of (i) an CXCR4 agonist, (ii) an EGFR agonist, (iii) an FGFR agonist, (iv) an Activin receptor agonist or an agent that stimulates SMAD3, (v) an IL11R agonist or IL6R agonist, (vi) a notch agonist, (vii) an RXR agonist or RAR agonist, or (viii) a BMP inhibitor for a time effective to allow the differentiation of pancreatic precursor cells from the human multipotent or pluripotent cells. | 12-24-2015 |
| 20150374798 | Methods of Treating Spinal Cord Injury - The invention is directed to a method of treating a spinal cord injury, a neurodegenerative disease or a neuronal injury in an individual in need thereof comprising administering an effective amount of superoxide dismutase (SOD) and catalase to the individual, wherein the superoxide dismutase and the catalase are encapsulated in one or more nanoparticles that release the SOD and catalase upon administration. Another aspect of the invention is directed to compositions comprising superoxide dismutase (SOD) and catalase encapsulated in one or more nanoparticles. | 12-31-2015 |
| 20160008287 | MICRONIZED INSULIN, MICRONIZED INSULIN ANALOGUES, AND METHODS OF MANUFACTURING THE SAME | 01-14-2016 |
| 20160008399 | COMPOSITIONS AND METHODS FOR DELIVERY OF IMMUNE CELLS TO TREAT UN-RESECTABLE OR NON-RESECTED TUMOR CELLS AND TUMOR RELAPSE | 01-14-2016 |
| 20160008472 | METAL-ORGANIC FRAMEWORKS WITH EXCEPTIONALLY LARGE PORE APERATURES | 01-14-2016 |
| 20160015638 | STABLE GLUCOKINASE ACTIVATOR COMPOSITIONS - The invention relates to stable pharmaceutical compositions comprising a glucokinase (GK) activator suitable for oral administration. The invention also relates to methods of making and using such pharmaceutical compositions. | 01-21-2016 |
| 20160015639 | Cyclodextrin Compositions Encapsulating a Selective ATP Inhibitor and Uses Thereof - The invention provides compositions comprising cyclodextrins encapsulating a selective ATP inhibitor, as well as uses thereof. | 01-21-2016 |
| 20160015824 | Lipid-Coated Albumin Nanoparticle Compositions and Methods of Making and Method of Using the Same - Lipid nanoparticle formulations, methods of making, and methods of using same are disclosed. | 01-21-2016 |
| 20160017043 | ANTI-VLA1 (CD49A) ANTIBODY PHARMACEUTICAL COMPOSITIONS - Formulations of anti-VLA-1 antibodies are described. | 01-21-2016 |
| 20160022824 | NANOPARTICLE COMPRISING HYDROPHOBIC DRUG CONJUGATED TO CATIONIC POLYMER AND HYDROPHILIC DRUG CONJUGATED TO ANIONIC POLYMER - The present invention relates to a nanoparticle including a hydrophobic drug conjugated to a cationic polymer and a hydrophilic drug conjugated to an anionic polymer, a method of preparing the same and a pharmaceutical use thereof. The nanoparticle according to an embodiment of the present invention may deliver the hydrophilic drug and the hydrophobic drug at the same time, and may control an initial drug burst. Further, the nanoparticle according to an embodiment of the present invention is specific to a cancer cell environment, and thus selective diagnosis or treatment of cancer cells is possible. | 01-28-2016 |
| 20160030522 | COMBINATION THERAPY TO IMPROVE SOFT TISSUE HEALING, FAT GRAFT HEALING, ENDOCHONDRAL BONE HEALING AND OSTEOINTEGRATION - The present invention is directed to kit, drug combinations and methods for promoting endogenous bone marrow (BM)-derived vasculogenic progenitor cell (PC) mobilization, sensitization of such cells and chemotaxis to the site of an injury such as injuries associated with osteointegration of implants and associated soft tissues, fat grafting and endochondral bone injuries and disease. | 02-04-2016 |
| 20160038433 | NANOCAPSULES OF PROTAMINE - The present invention relates to the design and development of nanocapsule systems for the administration of active substances, wherein the nanocapsules of the system have a mean diameter less than 1 μm and are characterized by comprising (a) a protamine shell, (b) an oily core, and one or more surfactants characterized by having a hydrophilic-lipophilic ratio greater than 8, provided that said surfactant is not a phospholipid. | 02-11-2016 |
| 20160038611 | Nanofibre and Bioactive Compositions and Related Methods - Described herein are compositions in nanofibre form including one or more bioactive compounds releasably incorporated thereon. In one embodiment a composition is described comprising at least one nanofibre and at least one bioactive compound. The nanofibres are formed from a base material that is solubilised with the bioactive or bioactives in an aqueous based solvent solution and the base material and bioactives are together spun via electrospinning to form dry fibres with the bioactives chemically bonded to the nanofibres and the bioactives remaining stable during storage of the composition under ambient conditions substantially free of moisture. On exposure to moisture, the nanofibres dissolve, thereby releasing the bioactives. | 02-11-2016 |
| 20160051697 | NANODELIVERY DEVICE FOR THERAPEUTIC LOADING OF CIRCULATING ERYTHROCYTES - According to one embodiment, a person's own RBCs can be recruited as secondary bioscavenger carriers in vivo using a nanopolymer-BChE complex, with an affinity ligand (antibody or peptide) for selective targeting to the RBCs and a cell-penetrating peptide for uptake into the RBCs. A general approach according to an embodiment involves parenteral administration of the nanodevice to gain access to the systemic circulation, which then seeks out and attaches to the person's RBCs, followed by transport into the RBCs (to minimize clearance from the circulation), leading to long-term circulation of the bioscavenger enzymes and thus protection against intoxication. | 02-25-2016 |
| 20160074327 | PROCESS FOR PREPARING MICROPARTICLES - A process for preparing microparticles comprising a biologically active material and a polymer and having a mean particle size expressed as the volume mean diameter (VMD) of from 10 to 500 μm, wherein the biologically active material is substantially insoluble in the polymer, which process comprises: a. contacting a mixture of the biologically active material or a precursor thereof, the polymer or a precursor thereof and a processing aid with a supercritical fluid which is capable of swelling the polymer under temperature and pressure conditions necessary to maintain the fluid in a supercritical state; b. allowing the supercritical fluid to penetrate and liquefy the polymer, whilst maintaining the temperature and pressure conditions so that the fluid is maintained in a supercritical state; c. releasing the pressure to precipitate microparticles comprising the biologically active agent and the polymer. | 03-17-2016 |
| 20160076038 | NANOPARTICLE MEDIATED DELIVERY OF siRNA - The invention provides multifunctional supramolecular self-assembled nanoparticles (SSNPs) comprising a set of rationally designed components that collectively facilitate efficient intestinal absorption of siRNA. The nanoparticles can induce potent TNF-α silencing in macrophages. Single gavage of SSNPs in mice depleted systemic TNF-α production at an siRNA dose as low as 50 μg/kg, and protected the mice from lipopolysaccharide-induced hepatic injury. | 03-17-2016 |
| 20160081932 | NEUTRALLY-CHARGED SYNTHETIC PLATELETS TO MITIGATE COMPLEMENT RESPONSE - The invention provides for compositions comprising nanoparticles comprising a core, water-soluble polymer and an RGD peptide and a poloxamer. | 03-24-2016 |
| 20160082086 | SUBMICRON PARTICLES FOR THE TREATMENT OF RADIATION DAMAGE IN PATIENTS - A method of treating a patient exposed to radiation before the patient is thrombocytopenic, comprising: intravenous infusion of protein spheres at a concentration of the protein spheres sufficient to reduce the morbidity and mortality of the irradiated patient. The protein spheres are formed from soluble proteins without the addition of surfactants or detergents, and the protein spheres spontaneously and directly bind at least one coagulation factor without the aid of other molecules which specifically bind the at least one coagulation factor. | 03-24-2016 |
| 20160082126 | NANOCOMPLEXES FOR DELIVERY OF SAPORIN - A nanocomplex, of particle size 50 nm to 1000 nm, containing saporin and a lipid-like compound, in which saporin binds to the lipid-like compound via non-covalent interaction or covalent bonding. The lipid-like compound has a hydrophilic moiety, a hydrophobic moiety, and a linker joining the hydrophilic moiety and the hydrophobic moiety. The hydrophilic moiety is optionally charged and the hydrophobic moiety has 8 to 24 carbon atoms. Also disclosed is a pharmaceutical composition containing such a nanocomplex and a pharmaceutically acceptable carrier. The nanocomplex is useful in treating diseases, such as cancer. | 03-24-2016 |
| 20160083693 | COMPOSITIONS AND METHODS FOR DIFFERENTIATING STEM CELLS INTO CELL POPULATIONS COMPRISING BETA-LIKE CELLS - Methods, kits, compositions, and systems are provided for culturing pluripotent stem cells to produce populations of cells comprising beta-like cells (e.g., pancreatic lineage, glucose-responsive, and/or insulin-producing). In particular, culture conditions are provided that result in the generation of beta-like cells from a starting culture of human pluripotent stem cells. | 03-24-2016 |
| 20160136232 | TUNABLE ANTI-MICROBIAL LOADED HYDROGELS - A tunable antimicrobial-loaded hydrogel formulation has a mechanical strength can be altered by changing the salt composition. The hydrogel formulation is preferably a Gellan film. The ion concentration in the gel material may be altered to obtain the desired gel strength. The hydrogel formulation is layered directly upon a skin area such as burnt skin. The hydrogel formulation includes a dosage of free antibiotic, such as the antibiotic is preferably vancomycin, for rapid release. The hydrogel formulation also includes microparticles and/or nanoparticles such as activated carbon powder that has adsorbed additional antibiotic. The particles are used to aid in attaining a timely or sustained release of the antibiotic drug. | 05-19-2016 |
| 20160143897 | CRYSTALLINE FREEBASE FORMS OF A BIPHENYL COMPOUND - The invention provides two crystalline freebase forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester. The invention also provides pharmaceutical compositions comprising the crystalline freebase or prepared using the crystalline freebases; processes and intermediates for preparing the crystalline freebases; and methods of using the crystalline freebases to treat a pulmonary disorder. | 05-26-2016 |
| 20160151286 | Hydrophilic Microparticles, Drug-Delivery Material, Method For Manufacturing Thereof And Methods For Delivery of A Drug-Delivery Composition | 06-02-2016 |
| 20160175251 | YEAST CELL WALL PARTICLES FOR RECEPTOR-TARGETED NANOPARTICLE DELIVERY | 06-23-2016 |
| 20160175461 | METHODS AND COMPOSITIONS FOR MODULATING SIALIC ACID PRODUCTION AND TREATING HEREDITARY INCLUSION BODY MYOPATHY | 06-23-2016 |
| 20160184429 | SYSTEMS AND METHOD FOR THE TREATMENT OF BLADDER CANCER - A chitosan material is treated in a nitrogen field by applying energy to ionize nitrogen in and around the chitosan, and the chitosan material is formulated into a hydrogel which can be utilized as a drug delivery vehicle for medicaments or therapeutic agents to treat certain conditions, such as cancers. | 06-30-2016 |
| 20160199489 | Etanercept Formulations Stabilized with Combinations of Sugars and Polyols | 07-14-2016 |
| 20170231915 | MICROSPHERES CONTAINING THERAPEUTIC AGENTS AND RELATED METHODS OF USE | 08-17-2017 |
| 20170231928 | SOLID COMPOSITION OF FINGOLIMOD AND PREPARATION THEREOF | 08-17-2017 |
| 20170232102 | HEMATOLOGIC CANCER TREATMENTS | 08-17-2017 |
| 20180021237 | ADHESIVE MATERIALS AND SEQUESTERED CURING AGENTS USED TO PRODUCE THEM | 01-25-2018 |
| 20180021264 | ALBUMIN NANOSPHERE PREPARATIONS TO CONTROL BLEEDING FROM SURGICAL OPERATIONS | 01-25-2018 |
